Accentia Biopharmaceuticals (ABPI) 10-Q 2006 Q3 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended June 30, 2006

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 000-51383

ACCENTIA BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Florida	04-3639490
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
324 South Hyde Park Ave., Suite 350 Tampa, Florida	33606
(Address of principal executive offices)	(Zip Code)

(813) 864-2554

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value $0.001 per share

(Title of class)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer    ¨ Accelerated filer    ¨ Non-accelerated filer    x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    ¨    Yes    x    No

As of July 31, 2006, there were 31,324,597 shares of the registrant’s Common Stock outstanding.

Forward-Looking Statements

Statements in this quarterly report on Form 10-Q that are not strictly historical in nature are forward-looking statements. These statements may include, but are not limited to, statements about: the timing of the commencement, enrollment, and completion of our clinical trials for our product candidates; the progress or success of our product development programs; the status of regulatory approvals for our product candidates; the timing of product launches; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; and our estimates for future performance, anticipated operating losses, future revenues, capital requirements, and our needs for additional financing. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” “goal,” and similar expressions intended to identify forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. The underlying information and expectations are likely to change over time. Actual events or results may differ materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the caption “Risk Factors” in “ITEM 1. BUSINESS” of our Form 10-K for the fiscal year ended September 30, 2006 and those set forth in our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

2

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Accentia Biopharmaceuticals, Inc.

INDEX TO FINANCIAL STATEMENTS

Accentia Biopharmaceuticals, Inc. and Subsidiaries Condensed Consolidated Financial Statements
Consolidated Balance Sheets as of June 30, 2006 and September 30, 2005	4
Consolidated Statements of Operations for the three months ended June 30, 2006 and 2005, and the nine months ended June 30, 2006 and 2005	7
Consolidated Statements of Stockholders’ Deficit for the nine months ended to June 30, 2006	8
Consolidated Statements of Cash Flows for the nine months ended June 30, 2006 and 2005	10
Notes to Consolidated Financial Statements	11

3

ACCENTIA BIOPHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2006 (Unaudited)			September 30, 2005 (Audited)
ASSETS
Current assets:
Cash and cash equivalents	$	189,271		$	2,763,452
Cash restricted		5,069,615			—
Accounts receivable:
Trade, net of allowance for doubtful accounts of $334,000 and $150,000 at June 30, 2006 and September 30, 2005, respectively		3,655,761			3,715,488
Stockholder		426,710			676,752
Inventories		1,534,331			1,013,896
Inventory deposits		964,633			844,740
Unbilled receivables		1,132,901			690,886
Prepaid expenses and other current assets		786,812			385,241
Total current assets		13,760,034			10,090,455
Goodwill		1,193,437			1,193,437
Other intangible assets:
Product rights		22,631,334			21,216,334
Non-compete agreements		2,104,000			2,104,000
Trademarks		1,634,659			1,631,474
Purchased customer relationships		1,268,950			1,268,950
Other intangible assets		648,288			648,040
Accumulated amortization		(7,311,531	)		(5,631,122	)
Total other intangible assets		20,975,700			21,237,676
Furniture, equipment and leasehold improvements, net		1,668,915			1,775,819
Deferred offering costs		—			821,573
Deferred finance costs		2,195,658			1,497,012
Other assets		355,595			64,621
	$	40,149,339		$	36,680,593

(Continued)

4

ACCENTIA BIOPHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(CONTINUED)

	June 30, 2006		September 30, 2005
	(Unaudited)		(Audited)
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Current maturities of long-term debt:
Related party	$	971,784	$	7,414,742
Other		6,214,783		8,888,847
Lines of credit		8,387,698		5,052,604
Accounts payable (including related party of $342,355 at June 30, 2006 and $346,423 at September 30, 2005 respectively)		5,870,117		5,519,626
Accrued expenses (including related party accrued interest of $85,408 at June 30, 2006 and $147,983 at September 30, 2005, respectively)		9,858,964		6,917,721
Unearned revenues		1,064,992		863,096
Product development obligations (including $-0- and $200,000 due to related party at June 30, 2006 and September 30, 2005, respectively)		300,000		500,000
Dividends payable		278,595		575,447
Stockholder note		350,000		350,000
Customer deposits		864,991		828,050
Deposits, related party		3,000,000		3,000,000
Derivative liability		306,750		10,802,825
Total current liabilities		37,468,674		50,712,958
Long-term debt, net of current maturities:
Related party		—		3,661,917
Other		6,479,801		4,902,666
Line of credit, related party		980,000		4,180,000
Other liabilities, related party		2,383,006		2,574,865
Total liabilities		47,311,481		66,032,406

(Continued)

5

ACCENTIA BIOPHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(CONTINUED)

	June 30, 2006			September 30, 2005
	(Unaudited)			(Audited)
Non-controlling interest in variable interest entity		3,600,000			—
Commitments and contingencies (Note 10)
Stockholders’ deficit:
Common stock, $0.001 par value; 300,000,000 shares authorized; 31,224,597 and 5,170,421 shares issued and outstanding at June 30, 2006 and September 30, 2005, respectively.		31,224			5,170
Preferred stock, Series A, $1.00 par value; 10,000,000 shares authorized; -0- and 2,937,013 shares issued and outstanding at June 30, 2006 and September 30, 2005, respectively.		—			6,183,000
Preferred stock, Series B, $1.00 par value; 30,000,000 shares authorized; -0- and 3,895,888 shares issued and outstanding at June 30, 2006 and September 30, 2005, respectively.		—			239,919
Preferred stock, Series C, $1.00 par value; 10,000,000 shares authorized; -0- and 3,562,607 shares issued and outstanding at June 30, 2006 and September 30, 2005, respectively.		—			7,500,000
Preferred stock, Series D, $1.00 par value; 15,000,000 shares authorized; -0- and 4,672,482 shares issued and outstanding at June 30, 2006 and September 30, 2005, respectively.		—			219,769
Preferred stock, Series E, $1.00 par value; 60,000,000 shares authorized; -0- and 20,506,178 shares issued and outstanding at June 30, 2006 and September 30, 2005, respectively.		—			49,789,554
Additional paid-in capital		133,632,598			24,851,870
Accumulated deficit		(144,425,964	)		(118,141,095	)
Total stockholders’ deficit		(10,762,142	)		(29,351,813	)
	$	40,149,339		$	36,680,593

See notes to condensed consolidated financial statements.

6

ACCENTIA BIOPHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the Three Months Ended						For the Nine Months Ended
				Restated						Restated
	June 30, 2006			June 30, 2005			June 30, 2006			June 30, 2005
Net Sales:
Products	$	2,310,225		$	2,722,798		$	8,016,305		$	8,106,009
Services		3,416,302			2,807,199			9,490,360			8,128,694
Related party, products		—			78,310			2,091,753			1,465,915
Total net sales		5,726,527			5,608,307			19,598,418			17,700,618
Cost of sales:
Products		1,129,203			1,026,220			3,518,326			3,254,144
Services		1,236,772			918,032			3,374,037			3,077,597
Total cost of sales (exclusive of amortization of acquired product rights)		2,365,975			1,944,252			6,892,363			6,331,741
Gross margin		3,360,552			3,664,055			12,706,055			11,368,877
Operating expenses:
Research and development		3,532,729			2,871,816			9,562,853			6,480,582
Research and development, related party		—			322,481			93,982			1,097,624
Sales and marketing		4,220,281			4,269,724			11,078,982			11,660,017
General and administrative		5,110,180			4,836,032			17,197,162			14,946,165
Royalties		438,597			488,666			1,258,359			1,108,142
Total operating expenses		13,301,787			12,788,719			39,191,338			35,292,530
Operating loss		(9,941,235	)		(9,124,664	)		(26,485,283	)		(23,923,653	)
Other income (expense):
Interest expense, net		(1,865,879	)		(268,838	)		(3,386,161	)		(659,243	)
Interest expense, net, related party		(321,979	)		(473,467	)		(1,042,076	)		(1,520,827	)
Loss on extinguishment of debt, related party		—			—			—			(2,361,894	)
Derivative gain (loss)		—			(230,709	)		2,883,035			(230,709	)
Other income (expense)		(2,827	)		27,847			94,206			(55,418	)
Loss from continuing operations before income taxes		(12,131,920	)		(10,069,831	)		(27,936,279	)		(28,751,744	)
Income tax benefit		—			—			—			—
Net loss from continuing operations		(12,131,920	)		(10,069,831	)		(27,936,279	)		(28,751,744	)
Absorption of prior losses against minority interest		210			150,000			1,690,010			150,000
Net loss		(12,131,710	)		(9,919,831	)		(26,246,269	)		(28,601,744	)
Constructive preferred stock dividend		—			—			—			(4,949,031	)
Preferred stock dividends, other		—			(101,529	)		(40,739	)		(395,596	)
Loss attributable to common stockholders	$	(12,131,710	)	$	(10,021,360	)	$	(26,287,008	)	$	(33,946,371	)
Weighted average shares outstanding, basic and diluted		30,220,618			5,162,627			26,649,244			5,139,893
Per share amounts, basic and diluted:
Net loss per share attributable to common stockholders	$	(0.40	)	$	(1.94	)	$	(0.99	)	$	(6.60	)

See notes to condensed consolidated financial statements.

7

ACCENTIA BIOPHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

FOR THE PERIOD FROM SEPTEMBER 30, 2005 TO JUNE 30, 2006

	Common Stock			Preferred Stock					Additional Paid-In Capital		Accumulated Deficit			Total
	Shares	Amount		Shares		Amount
Balances, September 30, 2005	5,170,421	$	5,170	35,574,168		$	63,932,242		$	24,851,870	$	(118,141,095	)	$	(29,351,813	)
Conversion of preferred shares to common stock	20,910,908		20,911	(35,574,168	)		(63,932,242	)		63,911,331		—			—
Issuance of common stock for cash at IPO	2,400,000		2,400	—			—			14,738,962		—			14,741,362
Biovest notes converted in Accentia common stock	493,842		494	—			—			3,740,303		—			3,740,797
Issuance of common stock, net of offering cost	1,647,000		1,647	—			—			7,719,073		—			7,720,720
Series E dividends converted to common stock	17,091		16	—			—			136,718		—			136,734
Note payable and accrued interest converted to common stock	412,892		413	—			—			3,302,720		—			3,303,133
Issuance of common stock for cash – options exercise	29,828		30	—			—			72,090		—			72,120
Issuance of common stock cashless exercise	142,615		143	—			—			—		—			143
Other comprehensive income	—		—	—			—			—		2,139			2,139
Stock-based compensation	—		—	—			—			934,422		—			934,422
Preferred stock dividends	—		—	—			—			—		(40,739	)		(40,739	)
Reclassification of derivative liability to equity	—		—	—			—			8,467,353		—			8,467,353
Issuance of warrants for financing costs	—		—	—			—			5,675,015		—			5,675,015
Issuance of common stock warrants for services	—		—	—			—			82,741		—			82,741
Net loss for the period	—		—	—			—			—		(26,246,269	)		(26,246,269	)
Balances, June 30, 2006	31,224,597	$	31,224	—		$	—		$	133,632,598	$	(144,425,964	)	$	(10,762,142	)

(Continued)

8

ACCENTIA BIOPHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

FOR THE PERIOD FROM SEPTEMBER 30, 2005 TO JUNE 30, 2006

(continued)

	Preferred Stock																									Total
	Series A					Series B					Series C					Series D					Series E
	Shares		Amount			Shares		Amount			Shares		Amount			Shares		Amount			Shares		Amount
Balances, September 30, 2005	2,937,013		$	6,183,000		3,895,888		$	239,919		3,562,607		$	7,500,000		4,672,482		$	219,769		20,506,178		$	49,789,554		$	63,932,242
Conversion of preferred shares to common stock	(2,937,013	)		(6,183,000	)	(3,895,888	)		(239,919	)	(3,562,607	)		(7,500,000	)	(4,672,482	)		(219,769	)	(20,506,178	)		(49,789,554	)		(63,932,242	)
Balances, June 30, 2006	—		$	—		—		$	—		—		$	—		—		$	—		—		$	—		$	—

See notes to condensed consolidated financial statements.

9

ACCENTIA BIOPHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Nine Months Ending June 30,
	2006			2005
Cash flows from operating activities:
Net loss	$	(26,246,269	)	$	(28,601,744	)
Adjustments to reconcile net loss to net cash flows from operating activities:
Loss on sale of assets		113,184			—
Derivative gain		(2,883,035	)		230,709
Depreciation		516,957			520,741
Amortization		1,621,435			2,115,971
Stock-based compensation		934,422			560,369
Accretion of debt discounts		1,094,036			37,899
Loss on conversion of shareholder debt to preferred stock		—			2,516,494
Issuance of common stock warrants		879,756			—
Absorption of prior losses against minority interest		(1,690,010	)		—
Other non-cash charges		27,337			(52,626	)
Increase (decrease) in cash resulting from changes in:
Accounts receivable		307,074			407,965
Inventories		(458,147	)		85,895
Inventory deposits		(119,893	)		—
Unbilled receivables		(436,660	)		26,667
Prepaid expenses and other current assets		497,580			(393,794	)
Other assets		(106,739	)		(226,864	)
Accounts payable		350,103			2,048,347
Accrued expenses		4,032,473			(2,261,600	)
Unearned revenues		196,541			(481,178	)
Customer deposits		(1,857	)		(35,468	)
Net cash flows from operating activities		(21,371,712	)		(23,502,217	)
Cash flows from investing activities:
Proceeds from sale of assets		14,803			—
Acquisition of furniture, equipment, and leasehold improvements		(689,130	)		(391,477	)
Cash paid for acquisition of product rights and other intangibles		(1,618,431	)		(4,299,659	)
Net cash flows from investing activities		(2,292,758	)		(4,691,136	)
Cash flows from financing activities:
Payments on notes payable and long-term debt		(10,144,911	)		(2,034,554	)
Proceeds from issuance of common stock		22,462,102			618,840
Proceeds from non-controlling investment in variable interest entity, net		3,000,000			—
Proceeds from issuance of preferred stock		—			19,077,327
Proceeds from the exercise of stock options		72,120			1,575,000
Proceeds from deposits and other liabilities		—			5,000,000
Proceeds from convertible debentures		—			5,000,000
Due from related party		(15,274	)		—
Proceeds from notes payable, stockholder		—			580,000
Payment of preferred stock dividends		(200,857	)		(316,311	)
Proceeds from line of credit		4,000,000			6,562,722
Payments to line of credit		(582,891	)		(4,739,000	)
Release from restricted cash		2,500,000			—
Proceeds from minority interest investment		—			150,000
Net cash flows from financing activities		21,090,289			31,474,024
Net change in cash and cash equivalents		(2,574,181	)		(3,280,671	)
Cash and cash equivalents at beginning of period		2,763,452			1,904,938
Cash and cash equivalents at end of period	$	189,271		$	5,185,609
Supplemental cash flow information:
Cash paid for:
Interest	$	1,947,379		$	1,102,360
Income taxes		—			—
Issuance of stock to satisfy accrued expense		—			—

10

ACCENTIA BIOPHARMACEUTICALS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NINE MONTHS ENDED JUNE 30, 2006 AND 2005

1. Description of the company

Accentia Biopharmaceuticals, Inc. and its subsidiaries, Analytica International, Inc. (“Analytica”), TEAMM Pharmaceuticals, Inc. (“TEAMM”), Accent RX, Inc. (“AccentRx”), Biovest International, Inc. (“Biovest”), and Accentia Specialty Pharmacy (“ASP”) (collectively referred to as the “Company” or “Accentia”) is a vertically integrated specialty biopharmaceutical company. The Company is a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. The Company has two product candidates entering or in Phase III clinical trials. The first product candidate, SinuNase^™, has been developed as a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis. The second product candidate, BiovaxID^™, is a patient-specific cancer vaccine focusing on the treatment of follicular non-Hodgkin’s lymphoma. BiovaxID is currently in a pivotal Phase III clinical trial. In addition to these product candidates, the Company has a growing specialty pharmaceutical business with a portfolio of marketed products and a pipeline of products under development by third parties.

2. Significant accounting policies

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been derived from unaudited interim financial information prepared in accordance with the rules and regulations of the Securities and Exchange Commission for quarterly financial statements. Certain information and note disclosures normally included in financial statement prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to those rules and regulation, although the Company believes that the disclosures made are adequate to make the information presented not misleading. The financial statements of the Company, in the opinion of management, include all normal and recurring adjustments necessary for a fair presentation of results as of the dates for the periods covered by the financial statements.

Operating results for the three and nine months ended June 30, 2006 are not necessarily indicative of the results that may be expected for the entire fiscal year. For Further information, refer to the financial statements and footnotes therto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2005.

Consolidation policy

The condensed consolidated financial statements represent the consolidation of wholly and majority owned companies and interests in joint ventures where the Company has a controlling financial interest or has been determined to be the primary beneficiary under FASB Interpretation No. 46 Consolidation of Variable Interest Entities (“FIN 46”). All significant intercompany balances and transactions have been eliminated.

Net loss per common share

The Company had net losses for all periods presented in which potential common shares were in existence. Diluted loss per share assumes conversion of all potentially dilutive outstanding common stock options, warrants, and other convertible instruments. Potential common shares outstanding are excluded from the calculation of diluted loss per share if their effect is anti-dilutive. As such, dilutive loss per share is the same as basic loss per share for all periods presented as the effect of all options, warrants, and other convertible instruments outstanding are anti-dilutive.

11

The following table sets forth the calculations of basic and diluted net loss per share:

	For the Three Months Ended						For the Nine Months Ended
	June 30, 2006			June 30, 2005			June 30, 2006			June 30, 2005
Numerator:
Net loss applicable to common stockholders	$	(12,131,710	)	$	(10,021,360	)	$	(26,287,008	)	$	(33,946,371	)
Denominator:
For basic loss per share—weighted average shares		30,220,618			5,162,627			26,649,244			5,139,893
Effect of dilutive securities					—			—			—
Weighted average shares for dilutive loss per share		30,220,618			5,162,677			26,649,244			5,139,893
Net loss per share applicable to common stockholders, basic and dilutive	$	(0.40	)	$	(1.94	)	$	(0.99	)	$	(6.60	)
EPS effect of preferred dividends	$	(0.00	)	$	(0.02	)	$	(0.00	)	$	(1.04	)

The effect of common stock equivalents are not considered in the calculation of diluted loss per share because the effect would be anti-dilutive. They are as follows:

	June 30, 2006	June 30, 2005
Options and warrants to purchase common stock	4,567,718	1,800,235
Convertible debt	2,082,290	1,438,849
Preferred stock convertible to common stock	—	33,197,902
Preferred stock options and warrants convertible to preferred which is then convertible to common	—	8,684,259

Stock-based compensation

In December 2004, the Financial Accounting Standards Board issued Statement No. 123R (FAS 123R), which revised FAS 123, “Accounting for Stock-Based Compensation,” by requiring the expensing of share-based compensation based on the grant-date value of the award. FAS 123 had provided companies the option of expensing such awards or merely disclosing the pro forma effects of such expensing in the notes to financial statements. As of October 1, 2002, Accentia began expensing employee stock options in accordance with FAS 123 and its related amendments. Accentia has now adopted FAS 123R. There are currently no significant differences between FAS 123 and FAS 123R; however FAS 123R also requires that an additional caption in the financial section of the Statements of Condensed Consolidated Cash Flows to present separately the excess tax benefits related to share based-payments. Because the Company has losses and deferred tax benefits of such losses are fully reserved, they have not yet inventoried such assets.

Reclassification:

Certain amounts in the 2005 financial statements have been reclassified to conform to the 2006 presentation.

3. Liquidity and management’s plans

The Company is projecting that operating cash flow deficits will be offset by net cash inflows from financing activities, such as debt or equity placements, accessing existing or new credit facilities, receipt of repayment of inter-company demand loans. At June 30, 2006, the Company had $5.3 million in cash, including $5.1 million restricted cash of which $5.2 million is cash held by its subsidiary Biovest; $3.3 million in potential availability under existing lines of credit, and $7.1 million in June 2006 in demand note receivable from Biovest. Of the $7.1 million demand note receivable, $4.0 million represents post-IPO cash advances. Upon Biovest obtaining additional financing, which it is seeking to consummate in calendar 2006, which may include equity offerings, debt financing, corporate collaborations, licensing transactions, or other forms of financing, it is anticipated that Biovest will repay some or all of the outstanding demand notes and Biovest will commence the funding of its ongoing operations without additional inter-company loans from Accentia.

12

Based on current operating plans the Company anticipates that its existing capital resource, together with potential future equity and debt financings by the Company and its subsidiary, Biovest, borrowing availability under its lines of credit and receipt or repayment of demand intercompany debt and the potential disposition of assets, products, or operations will be sufficient to fund its operation and development activities. The company is currently engaged in an effort to restructure certain of its existing indebtedness, and the Company also intends to seek additional financing through one or more private equity offerings, additional debt financings, corporate collaboration licensing transactions or disposition of assets, products or operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available from the foregoing sources, or if the Company determines it to otherwise be in the Company’s best interest, the Company may consider additional strategic financing options, including sales of assets or business units ( such as specialty pharmaceuticals, market services or cell culture equipment) that are non-essential to the ongoing development or future commercialization of SinuNase, or the Company may be required to delay, reduce the scope of, or eliminate one or more of its research or development programs or curtail some of its commercialization efforts.

There are currently no commitments in place for any debt and equity financing being sought by the Company or by Biovest, nor can assurances be given that such financing will be available. While the Company is confident that it will raise the capital necessary to fund operations and achieve successful commercialization of the products under development, there can be no assurances in that regard. The financial statements do not include any adjustments that may arise as a result of this uncertainty.

4. Inventories

Inventories consist of the following:

	June 30, 2006		September 30, 2005
Pharmaceutical products held for sale	$	1,203,243	$	814,862
Finished goods, other, net of $0.4 million allowance for obsolescence		33,273		35,787
Work-in-process		137,244		120,977
Raw materials		160,571		42,270
	$	1,534,331	$	1,013,896

5. Lines of credit

Lines of credit consists of the following:

	June 30, 2006		September 30, 2005
Secured revolving note of which $2.5 million is convertible due to Laurus Master Fund, Ltd., interest at prime plus 2% (10.25% at June 30, 2006); matures April 2008; principal and accrued interest convertible at fixed conversion price of $6.80 per share (See Note 9)	$	4,387,698	$	5,052,604
Bridge note related party, interest at 4.25%, unsecured, matures August 2007 or completion of a debt or equity financing resulting in more than $35.0 million in net proceeds (a)		980,000		4,180,000
Revolving credit agreement, interest at prime rate (8.25% at June 30, 2006); maturity in 2007; secured by Company’s accounts receivable and guarantee of major stockholder		4,000,000		—
	$	9,367,698	$	9,232,604
Less current maturities		8,387,698		5,052,604
	$	980,000	$	4,180,000

13

(a) This note provides up to $7.5 million in available borrowings from Hopkins II. The Company may prepay the bridge loan at any time without penalty or premium. However, on the date on which the bridge loan becomes due or on which the Company desires to prepay the loan, the Company must not be in default under its credit facility with Laurus Master Fund, Ltd., and the remaining balance under the Laurus credit facility at such time must be $2.5 million or less. If both of these conditions are not satisfied, then the bridge loan will not become due and cannot be paid until the first day on which both of these conditions are satisfied.

The Company has the unconditional right to borrow up to $5.0 million in the aggregate upon ten days’ prior written notice to Hopkins II. The Company’s right to borrow any amounts in excess of $5.0 million is conditioned upon the Company either being in default under its credit facility with Laurus or having less than $5.0 million cash on hand at the time of the advance. As of June 30, 2006, $1.0 million is outstanding under this bridge loan after conversion of $3.2 million in principal into common stock in May 2006, leaving potentially available borrowing capacity of $3.3 million. The loan is unsecured and bears interest at a rate equal to 4.25% per annum, simple interest. No payments of principal or interest are due until the maturity date of the loan.

Dr. Francis E. O’Donnell, our Chief Executive Officer and Chairman, is the sole manager of Hopkins II, and several irrevocable trusts established by Dr. O’Donnell collectively constitute the largest equity owners of Hopkins II.

Weighted average interest on all short-term borrowings aggregated 8.78% and 6.42% at June 30, 2006 and September 30, 2005 respectively. At June 30, 2006, the Company has an aggregate of $3.8 million available under its lines of credit.

6. Long-term debt

Long-term debt consists of the following:

	June 30, 2006			September 30 2005
Related party:
Term loan due to McKesson, a holder of shares of common stock and major supplier, payable at 10% contract rate (a)	$	—		$	3,900,000
Note due to McKesson, interest payable monthly at 10% (b)		800,000			2,095,414
Notes payable, former Biovest management, interest at 7%; due in 2006 (c)		—			4,439,328
Accrued interest (c)		171,784			641,917
		971,784			11,076,659
Less current maturities		(971,784	)		(7,414,742	)
	$	—		$	3,661,917
Other:
Convertible amortizing term note due to Laurus Master Fund, LTD., interest payable monthly at prime rate plus 4%; due April 2008 (d)(g)	$	6,701,876		$	6,496,127
Note payable, Harbinger Mezzanine Partners, LP, net of discount; secured by assets of TEAMM; interest payable monthly at 13.5%; $5.0 million principal balance matures August 2006 (e)		2,978,835			6,589,854
Convertible notes payable, Biovest bridge financing, due in 2006		—			100,000
Convertible notes payable, Biovest 2000 bridge financing, interest at 10%, due in 2006(f)		131,641			175,469
Note payable, Laurus Master Fund, Ltd. amortizing term note, interest payable monthly at the greater of prime rate plus 2% or 10.75%, due March 31, 2009 (g)		2,617,137			—
Note payable, former employee settlement		158,030			—
Other		107,065			119,050
Long term accrued interest		—			311,013
		12,694,584			13,791,513
Less current maturities		(6,214,783	)		(8,888,847	)
	$	6,479,801		$	4,902,666

Footnotes to long-term debt

(a) Note paid in full on November 2, 2005

14

(b) McKesson note was paid down to $0.8 million during the nine months ended June 30, 2006, balance is due August 2006.

(c) Note as of June 30, 2006 matures in 2006, accruing interest at 7.5% and paid monthly. Collateralized by certain assets of Biovest; convertible at the option of the holder into Biovest common stock (at $0.25 per share) or Accentia common stock (at a discount of $1.60 of the $8.00 IPO offering price). $4.3 million of notes as of September 30, 2005, due in 2007, were converted to equity during the three months ended December 1, 2005.

(d) Note is convertible into shares of common stock at $6.80 per share, exercisable through April 2008.

(e) Note was paid down to $2.8 million (net of discount) as of June 30, 2006, balance was paid in July 2006.

(f) Notes are convertible into shares of Biovest common stock at $1.00 per share and include warrants to purchase 50,000 shares of Biovest common stock at an exercise price of $1.25 per share, exercisable through September 2007.

(g) Discounts on long-term debt include the value of warrants issued in conjunction with long-term debt and are accreted over the life of the related debt. This debt provides for monthly payment provisions, a variable interest feature that includes a cap of 9.0% and a default put at 130% of face value for certain contingent events, including service defaults and changes in control, for the amortizing portion of the arrangement; these features are not present for unreleased, non-amortizing balances. The Company evaluated all terms and conditions of the amortizing notes for indications of embedded derivative financial instruments. While the interest rate cap was found to be clearly and closely related to the host instrument, the Company determined that the default put did not meet the clearly and closely related criteria as provided in FASB 133 Derivative Financial Instruments. Accordingly, upon release of funds underlying the first tranche, the Company reclassified an amount of $306,750 which represents the estimated fair value of the default put liability. The default put liability is initially and subsequently carried at fair value with changes recorded in income. Accordingly, the $306,750 is recorded as a derivative liability in the accompanying balance sheet on June 30, 2006.

Future maturities of long-term debt are as follows as of June 30, 2006:

Years ending June 30,
2007	$	8,140,232
2008		6,948,263
2009		5,784,661
		20,873,156
Less unamortized discount		(8,178,572	)
Total	$	12,694,584

The Laurus secured revolving note and term note is shown on the balance sheet under the following accounts:

Principal balance of notes	$	15,000,000
Less reduction for:
Fair value of beneficial conversion of options		(4,413,514	)
Fair value of warrants		(3,989,610	)
Recorded at closing		6,596,876
Accretion of discount (interest expense) through June 30, 2006 using effective interest method		846,930
Loss on extinguishment of debt		4,808,782
Debt payments		(1,163,014	)
Carrying value at June 30, 2006	$	11,089,574
As presented on balance sheet:
Current maturities of long-term debt-other	$	2,680,762
Lines of credit-current		4,387,698
Long-term debt, net of current maturities-other		4,021,114
	$	11,089,574

15

Derivation gain (loss) in the accompanying 2006 statement of operations associated with the above Laurus notes to the individual derivatives as follows:

	For the three months ended June 30,					For the nine months ended June 30,
	2006		2005			2006		2005
Free standing warrants	$	—	$	—		$	792,072	$	—
Embedded features		—		(230,709	)		2,090,963		(230,709	)
	$	—	$	(230,709	)	$	2,883,035	$	(230,709	)

7. Stockholders’ equity

During the nine months ended June 30, 2006, the following shares were converted to common stock at the initial public offering date (November 2, 2005):

Shares of Series A preferred stock for cash	2,937,014
Shares of Series B preferred stock for cash	1,990,796
Shares of Series C preferred stock for cash	1,478,482
Shares of Series D preferred stock for cash	2,214,746
Shares of Series E preferred stock for cash	12,289,870
Total common shares issued upon conversion of preferred stock	20,910,908

In addition to the conversion of preferred shares above, the following shares of common stock were issued during the nine months ended June 30, 2006:

142,615 shares upon the cashless exercise of warrants

493,842 shares upon the conversion of debt

29,828 for cash upon the exercise of stock options

2,400,000 shares for cash at IPO

17,091 shares upon conversion of dividends payable

412,892 shares upon conversion of Hopkins Capital Group II, LLC credit facility and accrued interest

1,647,000 shares for cash for private equity transaction

On February 13, 2005, the Company amended its Laurus financing arrangement, which amendment afforded exemptions, provided in FAS 133, to certain derivate elements that were previously recorded as liabilities. On the amendment, the Company fair valued such derivative liabilities, resulting in a charge to income in the amount of $2.8 million, and reclassed the remaining amounts to stockholders’ equity.

16

8. Operational results for Biovest

	For the three months ended June 30,
	2006						2005
	Biovest			Consolidated without Biovest			Biovest			Consolidated without Biovest
Net sales	$	2,051,667		$	3,674,860		$	1,476,098		$	4,132,209
Cost of sales		1,149,090			1,216,885			776,287			1,167,965
Gross margin		902,577			2,457,975			699,811			2,964,244
Operating expenses		3,748,294			9,553,493			3,188,009			9,600,719
Loss from operations		(2,845,717	)		(7,095,518	)		(2,488,198	)		(6,636,475	)
Interest income (expense)		(1,271,843	)		(916,015	)		(93,114	)		(649,191	)
Other income (expense)		—			(2,827	)		—			(202,862	)
Absorption of prior losses against minority interest		—			210			—			150,000
Net loss		(4,117,560	)		(8,014,150	)		(2,581,312	)		(7,338,528	)
Dividends		—			—			—			(101,527	)
Loss attributable to common stockholders		(4,117,560	)		(8,014,150	)		(2,581,312	)		(7,440,055	)
Weighted average shares outstanding, basic and diluted		30,220,618			30,220,618			5,162,627			5,162,627
Loss attributable to common stockholder per common share		(0.14	)		(0.27	)		(0.50	)		(1.44	)
	For the nine months ended June 30,
	2006						2005
	Biovest			Consolidated without Biovest			Biovest			Consolidated without Biovest
Net sales	$	5,425,638		$	14,172,780			4,086,566			13,614,052
Cost of sales		2,980,532			3,911,831			2,996,185			3,335,556
Gross margin		2,445,106			10,260,949			1,090,381			10,278,496
Operating expenses		10,856,794			28,334,544			8,714,864			26,577,675
Loss from operations		(8,411,688	)		(18,073,595	)		(7,624,483	)		(16,299,179	)
Interest income (expense)		(1,541,476	)		(2,886,761	)		(296,723	)		(1,883,347	)
Other income (expense)		42,841			2,934,400			—			(2,648,021	)
Absorption of prior losses against minority interest		—			1,690,010			—			150,000
Net loss		(9,910,323	)		(16,335,946	)		(7,921,206	)		(20,680,547	)
Dividends		—			(40,739	)		—			(5,344,627	)
Loss attributable to common stockholders		(9,910,323	)		(16,376,685	)		(7,921,206	)		(26,025,174	)
Weighted average shares outstanding, basic and diluted		26,649,244			26,649,244			5,139,893			5,139,893
Loss attributable to common stockholder per common share		(0.37	)		(0.61	)		(1.54	)		(5.06	)

9. Segment information

We define our segment operating results as earnings (loss) before general and administrative costs, interest expense, interest income, other income, discontinued operations and income taxes. Inter-segment sales were $0.05 and $0.7 million for the three months ended June 30, 2006 and 2005 respectively. Inter-segment sales were $0.2 million and $1.2 million for the nine months ended June 30, 2006 and 2005 respectively. Inter-segment sales represent the sale of services from the Biopharmaceutical Products and Services segment to the Specialty Pharmaceuticals segment and have been eliminated from segment sales.

17

Segment information for the three months ended June 30, 2006 is as follows:

	Biopharmaceutical Products and Services		Specialty Pharmaceuticals		Total
Net sales:
Products	$	1,197,645	$	1,112,580	$	2,310,225
Services		3,416,302		—		3,416,302
Total net sales		4,613,947		1,112,580		5,726,527
Cost of sales:
Products		510,409		618,794		1,129,203
Services		1,236,772		—		1,236,772
Total cost of sales		1,747,181		618,794		2,365,975
Gross margin		2,866,766		493,786		3,360,552
Sales and marketing		28,469		4,191,812		4,220,281
Research and development		3,532,729		—		3,532,729
Total assets		28,308,945		11,840,394		40,149,339
Goodwill		1,193,437		—		1,193,437

18

Segment information for the three months ended June 30, 2005 is as follows:

	Biopharmaceutical Products and Services		Specialty Pharmaceuticals		Total
Net sales:
Products	$	1,195,485	$	1,605,623	$	2,801,108
Services		2,807,199		—		2,807,199
Total net sales		4,002,684		1,605,623		5,608,307
Cost of sales:
Products		542,086		484,134		1,026,220
Services		918,032		—		918,032
Total cost of sales		1,460,118		484,134		1,944,252
Gross margin		2,542,566		1,121,489		3,664,055
Sales and marketing		396,362		3,873,362		4,269,724
Research and development		3,194,297		—		3,194,297
Total assets		26,540,587		10,262,184		36,802,771
Goodwill		1,193,437		—		1,193,437	1

Segment information for the nine months ended June 30, 2006 is as follows:

	Biopharmaceutical Products and Services		Specialty Pharmaceuticals		Total
Net sales:
Products	$	3,820,870	$	6,287,188	$	10,108,058
Services		9,490,360		—		9,490,360
Total net sales		13,311,230		6,287,188		19,598,418
Cost of sales:
Products		1,616,564		1,901,762		3,518,326
Services		3,374,037		—		3,374,037
Total cost of sales		4,990,601		1,901,762		6,892,363
Gross margin		8,320,629		4,385,426		12,706,055
Sales and marketing		438,635		10,640,347		11,078,982
Research and development		9,656,835		—		9,656,835
Total assets		28,308,945		11,840,394		40,149339
Goodwill		1,193,437		—		1,193,437

19

Segment information for the nine months ended June 30, 2005 is as follows:

	Biopharmaceutical Products and Services		Specialty Pharmaceuticals		Total
Net sales:
Products	$	3,006,699	$	6,565,225	$	9,571,924
Services		8,128,694		—		8,128,694
Total net sales		11,135,393		6,565,225		17,700,618
Cost of sales:
Products		1,742,227		1,511,917		3,254,144
Services		3,077,597		—		3,077,597
Total cost of sales		4,819,824		1,511,917		6,331,741
Gross margin		6,315,569		5,053,308		11,368,877
Sales and marketing		1,517,119		10,142,898		11,660,017
Research and development		7,578,206		—		7,578,206
Total assets		26,540,587		10,262,184		36,802,771
Goodwill		1,193,437		—		1,193,437

Domestic and foreign operations

Total assets and net losses of the Company’s foreign subsidiary were insignificant; however, total revenues aggregated approximately 21% of total revenues of the Company in the three months ended June 30, 2006. This entity, which is based in Germany, operates in the Biopharmaceutical Products and Services Segment and its general segment data is included therein. Segment information on a geographic basis for the three months ended June 30, 2006 is as follows:

	Domestic			International (Europe)		Total
Net sales	$	4,503,614		$	1,222,913	$	5,726,527
Net (loss) income		(12,304,947	)		173,237		(12,131,710	)
Total Assets		37,461,645			2,687,694		40,149,339
Goodwill		893,000			300,437		1,193,437

Total revenues from the foreign subsidiary aggregated approximately 17% of total revenues of the Company in the nine months ended June 30, 2006.

	Domestic			International (Europe)			Total
Net sales	$	16,258,629		$	3,339,789		$	19,598,418
Net loss		(26,028,090	)		(258,918	)		(26,287,008	)
Total Assets		37,461,645			2,687,694			40,149,339
Goodwill		893,000			300,437			1,193,437

20

Segment information on a geographic basis for the three months ended June 30, 2005 is as follows:

	Domestic			International (Europe)		Total
Net sales	$	4,366,869		$	1,241,438	$	5,608,307
Net (loss) income		(10,074,422	)		154,591		(9,919,831	)
Total Assets		34,208,362			2,594,409		36,802,771
Goodwill		893,000			300,437		1,193,437

Segment information on a geographic basis for the nine months ended June 30, 2005 is as follows:

	Domestic			International (Europe)		Total
Net sales	$	14,096,929		$	3,603,689	$	17,700,618
Net (loss) income		(29,008,483	)		406,739		(28,601,744	)
Total Assets		34,208,362			2,594,409		36,802,771
Goodwill		893,000			300,437		1,193,437

10. Commitments and contingencies

a) Operating leases

The Company has operating leases for various facilities, automobiles, machinery, and equipment, which expire at various times through 2011. The annual aggregate rental commitments under non-cancelable leases are as follows:

Year ending June 30,
2006	$	2,061,457
2007		1,572,383
2008		1,393,421
2009		1,126,429
2010		399,875
Thereafter		133,302
	$	6,686,867

Rent expense for all operating leases was approximately $0.8 million, and $0.4 million, for the three months ended June 30, 2006 and June 30, 2005, respectively. Rent expense for all operating leases was approximately $2.5 million, and $1.5 million, for the nine months ended June 30, 2006 and June 30, 2005, respectively.

Rental income from subleases aggregated $-0- and $0.1 million in the three months ended June 30, 2006 and June 30, 2005, respectively, and has been included in loss from discontinued operations in the accompanying statements of operations. Rental income from subleases aggregated $0.1 and $0.3 million in the nine months ended June 30, 2006 and June 30, 2005, respectively, and has been included in loss from discontinued operations in the accompanying statements of operations

b) Litigation

In October 2002, the Company’s subsidiary, AccentRx, Inc, acquired the assets and certain liabilities of American Prescription Providers, Inc. and American Prescription Providers of New York, Inc., collectively referred to as APP, which at the time of purchase operated a mail-order specialty pharmacy focused on filling prescriptions for AIDS patients and organ transplants. Commencing in late 1998, Dr. Francis E. O’Donnell (the Company’s Chairman and Chief Executive Officer) was the Chairman of the Board of APP, Dr. Dennis L. Ryll (a director of the Company) was a director of APP, and McKesson Corporation was APP’s principal lender. Also beginning in late 1998, The Hopkins Capital Group, LLC, an entity in which Dr. O’Donnell is the manager, and MOAB Investments, LP, an entity in which Dr. Ryll is a limited partner, were principal stockholders of APP. Following the purchase of APP’s assets,

21

AccentRx operated the mail-order business until it sold the assets of this business in December 2003 to a third-party in an arm’s length transaction. All of the sale proceeds from the disposition of this business were used to pay debts of AccentRx, including reducing the outstanding balance of the McKesson loan. After the sale of the APP assets, AccentRx ceased to engage in business, and AccentRx currently has nominal assets.

APP learned in May 2002 that the U.S. Department of Justice was conducting an industry-wide investigation under anti-kickback laws and other laws and regulations relating to purchases and sales of Serostim, an AIDS-wasting drug manufactured by Serono, Inc., from 1997 through 2000. As part of this investigation, in May 2002, APP received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts, and in March 2004, it received a federal grand jury subpoena seeking records related to Serostim prescriptions dispensed by APP, reimbursement claims submitted to Medicaid for Serostim, and APP’s relationships with Serono. The Company is not aware of any investigation into the acts of AccentRx or the Company with regard to the conduct of the mail-order pharmacy business following AccentRx’s purchase of APP’s assets. While the Company is uncertain as to the amount or measure of damages, if any, that may be sought from APP, based on information currently available to it, the Company estimates that, from the commencement of business by APP on December 1, 1998 through 2000, Serono paid APP approximately $500,000 under a program for data collection, and during this same period, Medicaid reimbursed APP approximately $6,000,000 for Serostim prescriptions filled by APP. The Company estimates that the majority of these payments from Serono and reimbursements from Medicaid were not attributable to APP’s mail-order business, but rather were attributable to APP’s retail pharmacies, which APP sold to a third party in February 2001 and were therefore not acquired by AccentRx as a part of the 2002 acquisition of APP’s assets. In May 2005, the U.S. Attorney’s Office notified APP that it believes that APP has significant potential liability as a result of allegedly unlawful rebates and discounts paid to them by Serono between 1997 and 2000. In August 2005, the U.S. Attorney’s Office orally and informally indicated to the Company’s legal counsel that, as a result of these allegedly unlawful rebates and discounts, it was considering instituting a civil action against AccentRx, the Company, APP (which has since dissolved and been liquidated), and shareholders of APP who received APP assets as a part of the liquidation of APP. However, it is not possible to predict the outcome of this investigation and whether the government will formally commence any action challenging any of APP’s prior programs and practices or APP’s liability or exposure as a result thereof. The Company is uncertain if any such action would be under the False Claims Act or other civil or criminal causes of action. In the event of litigation, the Company believes that APP will have defenses that will be vigorously asserted.

The Company cannot predict whether AccentRx or the Company could be held liable for the prior acts of APP as a result of AccentRx’s purchase of APP’s assets or whether the government will commence any actions against AccentRx. However, the Company believes that it is unlikely that the Company, which has always been operated as a distinct legal entity from AccentRx, will have material financial exposure in the event that AccentRx or APP incurs a material penalty in connection with this matter. Similarly, the Company does not believe that any adverse legal or regulatory determinations regarding APP, the Company, or AccentRx or any persons associated with APP, the Company, or AccentRx would have any material effect on the ability of the Company and its subsidiaries to conduct their current or expected business operations. On October 17, 2005, the U.S. Department of Justice announced a settlement of criminal and civil allegations against Serono. According to the terms of the settlement, Serono, together with its U.S. subsidiaries and related entities, agreed to pay $704 million in connection with illegal schemes to promote, market, and sell its drug Serostim. The Company cannot predict the impact, if any, that this settlement will have on the government’s investigation relating to APP’s purchases and sales of Serostim.

Except for the foregoing, the Company not a party to any material legal proceedings, and management is not aware of any threatened legal proceedings that could cause a material adverse impact on its business, assets, or results of operations.

Further, from time to time the Company is subject to various legal proceedings in the normal course of business, some of which is covered by insurance. Management believes that these proceedings will not have a material adverse effect on the financial statements.

11. New Market Tax Credit Financing

On April 25, 2006, Biovest, through its wholly-owned subsidiary, Biovax, Inc. (“Biovax”) became the recipient of $3.0 million in net-funds under a qualified New Market Tax Credit Program (“NMTC”). The NMTC was provided for in the Community Renewal Tax Relief Act of 2000 (the “Act”) and is intended to induce investment capital in underserved and impoverished areas of the United States. The Act permits taxpayers (whether companies or individuals) to claim credits against their Federal income taxes for up to 39% of qualified investments in qualified, active low-income businesses or ventures. Biovax is a qualified, active low-income business and is eligible to receive investment capital under the NMTC.

NMTC investments are made though Community Development Entities (“CDE”); such entities are qualified for this purpose through the U.S. Department of the Treasury. The CDE investor in the Company’s financing arrangement is Telesis CDE II, LLC, which was

22

established solely for this investment. Telesis CDE II, LLC is managed and partially owned (0.01%) by Telesis CDE Corporation, which is a private financial institution. The remaining equity interest in Telesis CDE II, LLC (99.99%) is owned by Biovax Investments, LLC (the “Fund”), a company established solely for the purpose of facilitating this NMTC financing arrangement. The Fund equity is owned 99.99% by US Bancorp and 0.01% by Telesis CDE Corporation.

The fund was capitalized with $3.6 million equity from US Bancorp and a nominal equity investment by Telesis CDE Corporation. In addition, Biovest and the Company, through a consolidated subsidiary, loaned $8.5 million to the Fund pursuant to a 5.18%, annual rate, senior-secured, convertible note receivable, due in seven and one-half years. The note is convertible at the option of the Fund into shares of Biovest’s common stock at a price based upon trading market prices of Biovest’s common stock near the maturity date in seven and one-half years. These proceeds received by the Fund from the aforementioned financing transactions were used to make a contemporaneous 99.99% equity investment in Telesis CDE II, LLC ($12.0 million) and payment for management, legal and accounting fees ($0.1 million).

Telesis CDE II, LLC, upon receipt of its equity funding, contemporaneously issued $11.5 million to Biovax for (a) a 1.0% convertible promissory note payable, due in seven and one-half years, (b) warrants to purchase 1.2 million shares of Biovest’s common stock over a period of nine-years at a fixed price of $9.00 and (c) warrants to purchase 0.2 million shares of the Company’s common stock over a period of seven years at a fixed price of $1.30. The convertible promissory note is convertible into common stock at the option of Telesis CDE II, LLC within 5 days of the maturity date at a conversion price equaling the then trading market price of the common stock. The overall arrangement provides that in the event Telesis CDE II, LLC converts the note payable, the aforementioned note receivable is subject to immediate conversion at the same conversion price.

Other salient terms and conditions of the NMTC financing arrangement are as follows:

1. The new market tax credits arising from this transaction were fully assigned to US Bancorp. Biovest, its subsidiaries and certain related parties have entered into an indemnification agreement directly with US Bancorp that provides for indemnification in the event of tax credit recapture from events caused by the Company. Examples of events that would cause recapture are relocation out of the qualified zone or disqualification from changes in Biovax’s employment mix. An example of an event that would not cause a recapture is a change in the Internal Revenue Code that results in such recapture. The total indemnification amount could be $4.7 million (representing 39% of the $12.0 million qualified investment). However, in accordance with Financial Interpretation 45 Guarantor’s Accounting and Disclosure Requirements for Guarantees, including Indirect Guarantees of the Indebtedness of Others, the conditions and events that could result in recapture are within Biovest’s control. Therefore, the financial statements do not reflect a liability for this indemnification at June 30, 2006.

2. In connection with the NMTC financing, the Company and US Bancorp entered into a put option wherein US Bancorp will have the right to put it’s investment in the Fund to Biovest near the maturity of the instruments at a price of $180,000. The counterparties also extended a purchase option to Biovest to purchase US Bancorp’s interest in the fund near the maturity date at fair value. These instruments were evaluated pursuant to the provisions of FAS133 and it was concluded that the put liability required recognition in Biovest’s financial statements because it is highly probable that, upon maturity, US Bancorp will put its investment in the Fund to the Company.

3. Biovest, its subsidiaries and certain related parties have entered into a guarantee arrangement with Telesis CDE II, Inc. for the debt service of Biovax. In addition, the Company has partially guaranteed debt service with limitations established at no greater than $60,000 each year the instrument is outstanding. Biovest issued warrants to purchase 1.0 million shares of common stock to the related parties as compensation for their guarantees. The guarantees were treated in a manner similar to contributed service and the fair value of the warrants issued for consideration was charged to expense upon issuance.

Accounting for the NMTC financing arrangement:

The Company evaluated the structure of the NMTC financing arrangement and entities so involved under the context of FIN46. FIN46 provides a framework for determining whether certain entities should be consolidated (irrespective of equity ownership) based upon a variable interests model. This model determines the control and consolidation based upon potential variability in gains and losses of the entity being evaluated for consolidation. Generally, a variable interest holder that absorbs a majority of the entity’s expected losses, if they occur, receives a majority of the entity’s expected residual return, if they occur, or both is identified as the primary beneficiary for consolidation purposes.

23

The Company concluded that the Fund and Telesis CDE II, LLC met the definition of variable interest entity. However, for Biovest to be required to apply the provisions of the Interpretation, it must have a variable interest in the entity. Variable interests in a variable interest entity are contractual, ownership or other money interests in an entity that change with changes in the value of the net assets of the entity. The following table illustrates the variable interests have been identified in each of the entities considered by the Company and the related holder:

Variable Interest Holder	Variable Interests Fund	Variable Interests Telesis CDE II, LLC
Biovest and its Related Parties	Senior beneficial interest Guaranty Agreement Indemnification Agreement Put (VIE Equity) Call (VIE Equity)	Senior beneficial interest Guarantee Agreement Call (Biovest Equity)
Fund		VIE Equity (99.9%)
US Bancorp	VIE Equity (99.9%)	Tax Credit Rights
Biovest Investment Corp.	VIE Equity (0.01%)
Telesis CDE, Inc.		VIE Equity (0.01%)

The above table illustrates the weight of the variable interests that are held by Biovest. In addition, in performing quantitative valuation, the Company afforded significant weight to the guarantee agreement, indemnification and put feature, the preponderance of which limit the equity investor’s risk of loss on the venture. In evaluating both qualitative and quantitative considerations, the Company has concluded that its variable interests in the entity absorb most of the entities’ losses and should, therefore, consolidate the entities under the scope of FIN46.

The assets and liabilities of the variable interest entities, identified above, are limited to the instruments referred to in the description of the NMTC financing arrangement above. In accordance with consolidation principles, these assets and liabilities are eliminated in consolidation leaving the non-controlling interests of US Bancorp and Telesis CDE Corporation reflected on Biovest’s balance sheet. All intercompany accounts will continue to be eliminated so long as (i) the entities meet the definition of variable interest entities and (ii) Biovest is the primary beneficiary.

12. Subsequent Events

On July 3, 2006, the Company entered into a Forebearance Agreement regarding its outstanding credit facility with Harbinger Mezzanine Partners, L.P. (“Harbinger”), whereby Harbinger agreed to forebear in connection with seeking additional payments of remaining $3.0 million in principal and interest due under this obligation until the earliest of August 3, 2006, a sale of assets by the Company, or closing of an additional financing transaction. The remaining principal and accrued interest was paid on July 13, 2006.

On July 13, 2006, the Company entered into an amendment to its credit facility with Laurus Master Fund, Ltd. (“Laurus”) under which the amount of the aggregate overadvance by Laurus to the Company under such credit facility was increased to $7.5 million. The purpose of the overadvance increase was to obtain new funding in the approximate amount of $5.0 million (before transaction expenses) to refinance the indebtedness of TEAMM Pharmaceuticals, Inc., a wholly owned subsidiary of the Company (“TEAMM”), to Harbinger Mezzanine Partners, LP. The terms of the increased overadvance are set forth in an overadvance letter agreement, dated July 13, 2006, among Laurus, the Company, and certain subsidiaries of the Company (the “Overadvance Agreement”).

24

As required by the Overadvance Agreement, approximately $3.0 million of the newly advanced funds from Laurus were used to repay in full the remaining outstanding balance under the loan from Harbinger Mezzanine Partners, LP to TEAMM. The Company previously paid $2.0 million under the Harbinger indebtedness on June 30, 2006 from cash on hand. The remaining new funds from the Overadvance after transaction expenses are being used for general corporate purposes.

The other material terms and conditions of the Overadvance Agreement are as follows:

• Immediately following the execution and delivery of the Overadvance Agreement, the Company will make a new borrowing under its revolving credit facility with Laurus against the eligible accounts receivable and eligible inventory of TEAMM, and such borrowing will be used to pay down the Overadvance. The Company anticipates that the amount of such borrowing will be approximately $2.5 million. Accordingly, the Overadvance Agreement provides that the maximum amount of the Overadvance will be automatically reduced to $5.0 million (from $7.5 million) as of July 31, 2006.

• Any portion of the Overadvance still outstanding on January 1, 2007 will be due and payable on January 1, 2007. However, if prior to January 1, 2007, the Company engages in any sale of all or any portion of its equity interest in TEAMM, or if TEAMM sells all or any portion of its assets (other than the sale of inventory in the ordinary course of business or certain sales of obsolete or unnecessary equipment), then the Overadvance must be repaid in an amount, to be determined by Laurus, up to the net proceeds received from such transaction.

• The Overadvance will bear interest at the prime rate plus two percent (2.0%) per annum.

• In consideration of the Overadvance and as provided in the Overadvance Agreement, the Company paid to Laurus a $175,000 servicing payment and issued to Laurus 100,000 shares of fully paid and nonassessable shares of the Company’s common stock, par value $.001 per share.

• The Overadvance Agreement grants to Laurus piggyback registration rights with respect to the Company shares issued to Laurus under the agreement, subject to the prior registration rights of other third parties and subject to the right of an underwriter in an underwritten offering to reduce the shares being sold by Laurus under customary circumstances.

The shares issued by the Company to Laurus under the Overadvance Agreement were issued pursuant to an exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”), by virtue of Section 4(2) of the Securities Act and by virtue of Rule 506 of Regulation D under the Securities Act. Such sale and issuance did not involve any public offering, was made without general solicitation or advertising, and Laurus represented to the Company that Laurus is an accredited investor with access to all relevant information necessary to evaluate the investment and that the shares were being acquired for investment purposes only.

On July 20, 2006, the Company entered into an amendment to its Option Agreement with Mayo Foundation for Medical Education and Research (“MAYO”) under which the Company’s exclusive option to elect to expand its license for the use of all antifungals including non-prescription over-the-counter formulations for the treatment of chronic sinusitis (chronic rhinosinusitis), was extended for an additional one-year period through and including December 10, 2007. This Amendment becomes effective upon payment of the cash consideration as described hereinafter. As previously announced, the Company has a worldwide exclusive license to the prescription antifungal, amphotericin B. During this exclusive option period MAYO has agreed that it may not discuss licensing of this technology for use with any other compound with any other potential license partner worldwide.

In consideration of the Amendment to Option Agreement, the Company has agreed to pay to MAYO cash consideration of $100,000 and issued to MAYO warrants to purchase up to 25,000 shares of the Company’s common stock, par value $.001 per share, at an exercise price of $3.50 per share. The warrants issued by the Company to MAYO under the Amendment to Option Agreement were issued pursuant to an exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”), by virtue of Section 4(2) of the Securities Act and by virtue of Rule 506 of Regulation D under the Securities Act. Such sale and issuance did not involve any public offering, was made without general solicitation or advertising, and MAYO represented to the Company that MAYO is an accredited investor with access to all relevant information necessary to evaluate the investment and that the shares were being acquired for investment purposes only.

25

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

When you read this section of this Quarterly Form 10Q, it is important that you also read the financial statements and related notes included elsewhere in this Form 10Q. This section of this quarterly report contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations, and intentions. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the matters discussed under the caption “Risk Factors” in “Item 1, BUSINESS” in our annual report on Form 10-K for the fiscal year ended September 30, 2005 and other risks and uncertainties discussed in filings made with the Securities and Exchange Commission.

Overview

We are a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. We have two product candidates entering or in Phase 3 clinical trials. One of these product candidates, SinuNase, has been developed at Mayo Clinic as a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis, a long-term inflammatory condition of the paranasal sinuses for which there is currently no FDA approved therapy. We submitted an Investigational New Drug Application, or IND, with the FDA for SinuNase in April 2005, and the IND was accepted by the FDA in May 2005. We received fast track status for SinuNase April 2006. We expect to commence our Phase 3 clinical trial for the product in 2006. Our other late-stage product candidate, BiovaxID^™, is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin’s lymphoma. BiovaxID was developed at the National Cancer Institute and is currently in a pivotal Phase 3 clinical trial. In May 2006, the FDA granted fast track status to BiovaxID, which means that the Company is now eligible to submit a biologics license application (BLA) on a rolling basis, allow the FDA to review sections of the BLA in advance of receiving the Company’s full submission and permitting the Company to apply for expedited review of its BLA. In addition to these product candidates, we have a growing specialty pharmaceutical business with a portfolio of currently marketed pharmaceutical products and a pipeline of additional products under development by third parties. In addition to our late-stage product candidates and our specialty pharmaceutical business, we have a broad range of in-house capabilities and resources that we market to third parties and use to develop and commercialize our own products. These capabilities include analytical and consulting services relating to the biopharmaceuticals industry, such as pricing and market assessment, reimbursement strategies, clinical trial services, and outcomes research. We also produce custom biologics and cell culture systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported net sales and expenses during the reporting periods.

The accounting policies discussed below are considered by our management to be critical to an understanding of our financial statements because their application depends on management’s judgment, with financial reporting results relying on estimates and assumptions about the effect of matters that are inherently uncertain. On an ongoing basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. For all of these policies, management cautions that future events rarely develop exactly as forecast and that best estimates routinely require adjustment. Accordingly, actual results may differ from our estimates under different assumptions or conditions and could materially impact our financial condition or results of operations.

While our significant accounting policies are more fully described in Note 2 to our September 30, 2005 consolidated financial statements, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results.

26

Revenue recognition

Biopharmaceutical Products and Services

We recognize revenue in our Biopharmaceutical Products and Services segment as follows:

Products.Net sales of cell culture instruments and disposables are recognized in the period in which the applicable products are delivered. We do not provide our customers with a right of return; however, deposits made by customers must be returned to customers in the event of non-performance by us.

Services.Service revenue in our Biopharmaceutical Products and Services segment is generated primarily by fixed-price contracts for cell culture production and consulting services. Such revenue is recognized over the contract term in accordance with the percentage-of-completion method based on the percentage of service cost incurred during the period compared to the total estimated service cost to be incurred over the entire contract. The nature and scope of our contracts often require us to make judgments and estimates in recognizing revenues.

Estimates of total contract revenues and costs are continuously monitored during the term of the contract, and recorded revenues and costs are subject to revision as each contract progresses. Such revisions may result in increases or decreases to revenues and income and are reflected in the condensed consolidated financial statements in the periods in which they are first identified. Each month we accumulate costs on each contract and compare them to the total current estimated costs to determine the percentage of completion. We then apply this percentage to the total contract value to determine the amount of revenue that can be recognized. Each month we review the total current estimated costs on each contract to determine if these estimates are still accurate and, if necessary, we adjust the total estimated costs for each contract. As the work progresses, we might decide that original estimates were incorrect due to, among other things, revisions in the scope of work, and a contract modification might be negotiated with the customer to cover additional costs. If a contract modification is not agreed to, we could bear the risk of cost overruns. Losses on contracts are recognized during the period in which the loss first becomes probable and reasonably estimable. Reimbursements of contract-related costs are included in revenues. An equivalent amount of these reimbursable costs is included in cost of sales. Because of the inherent uncertainties in estimating costs, it is at least reasonably possible that the estimates used will change within the near term.

Service costs related to cell culture production include all direct materials and subcontract and labor costs and those indirect costs related to contract performance, such as indirect labor, insurance, supplies, and tools. We believe that actual cost incurred in contract cell production services is the best indicator of the performance of the contractual obligations, because the costs relate primarily to the amount of labor incurred to perform such services. The deliverables inherent in each of our cell culture production contracts are not output driven, but rather driven by a pre-determined production run. The duration of our cell culture production contracts range typically from 2 to 14 months.

Service costs relating to our consulting services consist primarily of internal labor expended in the fulfillment of our consulting projects and, to a lesser extent, outsourced research services. Service costs on a specific project may also consist of a combination of both internal labor and outsourced research service. Our consulting projects are priced and performed in phases, and the projects are managed by phase. As part of the contract bidding process, we develop an estimate of the total number of hours of internal labor required to generate each phase of the customer deliverable (for example, a manuscript or database), and the labor cost is then computed by multiplying the hours dedicated to each phase by a standard hourly labor rate. We also determine whether we need services from an outside research or data collection firm and include those estimated outsourced costs in our total contract cost for the phase. At the end of each month, we collect the cumulative total hours worked on each contract and apply a standard labor cost rate to arrive at the total labor cost incurred to date. This amount is divided by the total estimated contract cost to arrive at the percentage of completion, which is then applied to the total estimated contract revenues to determine the revenue to be recognized through the end of the month. Accordingly, as hours are accumulated against a project and the related service costs are incurred, we concurrently fulfill our contract obligations. The duration of our consulting service contracts range typically from 1 to 12 months. Certain other professional service revenues, such as revenues from maintenance services on cell culture equipment, are recognized as the services are performed.

In our financial statements, unbilled receivables represents revenue that is recognizable under the percentage-of-completion method due to the performance of services for which billings have not been generated as of the balance sheet date. In general, amounts become billable pursuant to contractual milestones or in accordance with predetermined payment schedules. Under our consulting services contracts, the customer is required to pay for contract hours worked by us (based on the standard hourly rate used to calculate the contract price) even if the customer cancels the contract and elects not to proceed to completion of the project. Unearned revenues represent customer payments in excess of revenue earned under the percentage-of-completion method. Such payments are made in accordance with predetermined payment schedules set forth in the contract.

27

Specialty Pharmaceuticals

Revenue in our Specialty Pharmaceuticals segment is generated from the sale of pharmaceutical products. Revenue from product sales is recognized when all of the following occur: a purchase order is received from a customer; title and risk of loss pass to our customer upon the receipt of the shipment of the merchandise under the terms of FOB destination; prices and estimated sales provisions for product returns, sales rebates, payment discounts, chargebacks, and other promotional allowances are reasonably determinable; and the customer’s payment ability has been reasonably assured. An estimate of three business days from the time the product is shipped via common carrier until it reaches the customer is used for purposes of determining FOB destination. Revenues in connection with co-promotion agreements are recognized based on the terms of the agreements.

We make periodic adjustments to our monthly net sales for estimated chargebacks, rebates, and potential product returns we anticipate might ultimately be required. These adjustments are based on inventory quantity reports provided by our largest wholesale customers, sales activity reports generated by group purchasing organizations with which we have rebate contracts, and sales activity data provided by a third-party provider of such data. Our reserves currently reflect an adjustment of 9% of gross sales for charge-backs/rebates and 13% for product returns that we record in the form of a reserve.

Actual product returns, chargebacks, and other sales allowances incurred are dependent upon future events and may be different than our estimates. We continually monitor the factors that influence sales allowance estimates and make adjustments to these provisions when management believes that actual product returns, chargebacks, and other sales allowances may differ from established allowances.

Inventories

Inventories are recorded at the lower of cost or market. We periodically review inventory quantities of raw materials, instrumentation components and disposables on hand, and completed pharmaceutical products in our third-party distribution center, and we record write-downs of inventories to market value based upon contractual provisions and obsolescence, as well as assumptions about future demand and market conditions. If assumptions about future demand change and/or actual market conditions are less favorable than those projected by management, additional write-downs of inventories may be required.

Inventory in our Biopharmaceutical Products and Services segment includes raw materials and component parts used in the assembly of instruments and cultureware for our Biovest subsidiary. Estimates for obsolete and unsaleable inventory are determined by management and updated quarterly.

Specialty Pharmaceuticals inventory consists primarily of trade products and samples. These inventories are warehoused at a third-party distribution center located in Memphis, Tennessee. All distribution, inventory control, and regulatory reporting are outsourced to this third party. Inventories are written-off if the product dating has expired or the inventory has no market value.

Valuation of Goodwill and Intangible Assets

Our intangible assets include goodwill, trademarks, product rights, non-compete agreements, technology rights, purchased customer relationships, and patents, all of which are accounted for based on Financial Accounting Standard Statement No. 142Goodwill and Other Intangible Assets(“FAS 142”). As described below, goodwill and intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets with limited useful lives are amortized using the straight-line method over their estimated period of benefit, ranging from two to eighteen and one-half years. We obtain a valuation of all intangibles purchased in any acquisition and undertake an annual impairment analysis. Goodwill is tested for impairment by comparing the carrying amount to the estimated fair value, in accordance with SFAS 142. Impairment exists if the carrying amount is less than its estimated fair value, resulting in a write-down equal to the difference between the carrying amount and the estimated fair value. We have made no impairment adjustments to recorded goodwill. Our carrying value of goodwill at June 30, 2006 and September 30, 2005 was $1.2 million. The values recorded for goodwill and other intangible assets represent fair values calculated by accepted valuation methods. Such valuations require critical estimates and assumptions derived from and which include, but are not limited to: (i) information included in our business plan, (ii) estimated cash flows, (iii) discount rates, (iv) patent expiration information, (vi) terms of license agreements, and (vii) expected timelines and costs to complete any in-process research and development projects to commercialize our products under development.

28

We capitalized goodwill in the amount of $0.9 million in connection with our acquisition of Analytica in April 2002. In connection with the foreign subsidiary acquisition in December 2003, we initially capitalized goodwill in the amount of $0.6 million based on the fair value of the acquired assets net of assumed liabilities. Following this acquisition, we discovered that the assumed liabilities were $0.3 million in excess of the amount represented to us in the acquisition agreement. We recorded an impairment to goodwill in the amount of $0.3 million in the fiscal quarter in which the acquisition occurred.

Our major intangible assets with limited useful lives include product rights acquired in connection with our April 2003 acquisition of TEAMM and our June 2003 acquisition of Biovest, as well as a variety of patents, non-competition rights, and purchased customer relationships. We amortize intangibles based on their expected useful lives and look to a number of factors for such estimations, including the longevity of our license agreements and the remaining life of patents on products currently being marketed. We have identified several trademarks, product rights and technology rights as intangible assets with indefinite lives.

Impairment Testing

Our impairment testing is calculated at the reporting unit level. Our annual impairment test, last performed as of September 30, 2005, has two steps. The first identifies potential impairments by comparing the fair value of the reporting unit with its carrying value. If the fair value exceeds the carrying amount, intangible assets are not impaired and the second step is not necessary. If the carrying value exceeds the fair value, the second step calculates the possible impairment loss by comparing the implied fair value of intangible assets with the carrying amount. If the implied fair value of intangible assets is less than the carrying amount, a write-down is recorded. Impairment would result in a write-down of the intangible asset to its estimated fair value based on the discounted future cash flows. The impairment test for the intangible assets is performed by comparing the carrying amount of the intangible assets to the sum of the undiscounted expected future cash flows.

In accordance with SFAS 144, which relates to impairment of long-lived assets, impairment exists if the sum of the future undiscounted cash flows is less than the carrying amount of the intangible asset or to its related group of assets. Goodwill is tested for impairment by comparing the carrying amount of the reporting unit to which it was assigned to the estimated fair value of the reporting unit. In accordance with SFAS 142, which relates to impairment of goodwill, impairment exists if the carrying amount of the reporting unit is less than its estimated fair value. Impairment would result in a write-down equal to the difference between the carrying amount and the estimated fair value of the reporting unit. Fair values can be determined using income, market or cost approaches.

We predominately use a discounted cash flow model derived from internal budgets in assessing fair values for our goodwill impairment testing. Factors that could change the result of our goodwill impairment test include, but are not limited to, different assumptions used to forecast future net sales, expenses, capital expenditures, and working capital requirements used in our cash flow models. In addition, selection of a risk-adjusted discount rate on the estimated undiscounted cash flows is susceptible to future changes in market conditions, and when unfavorable, can adversely affect our original estimates of fair values. In the event that our management determines that the value of intangible assets have become impaired using this approach, we will record an accounting charge for the amount of the impairment.

Purchased In-Process Research and Development

We account for purchased in-process research and development, or IPR&D, in accordance with pronouncements as follows:

• FASB Statement of Financial Accounting Standards No. 2,Accounting for Research and Development;

• FASB Interpretation No. 4,Applicability of FASB Statement No. 2 to Business Combinations Accounted for by the Purchase Method; and

• FASB Statement of Financial Accounting Standards No. 86,Accounting for the Costs of Computer Software to be Sold, Leased or Otherwise Marketed.

Generally, purchased in-process research and development is distinguished from developed technology based upon whether the IPR&D projects are measurable, have substance, and are incomplete. IPR&D represents the portion of a purchase price of an acquisition related to research and development activities that have not demonstrated technological feasibility and do not have alternative future uses. IPR&D projects that have not been granted FDA approval are classified as being incomplete, and as such the associated costs are expensed as incurred. In connection with the acquisition of our Biovest subsidiary in June 2003, we incurred an immediate writedown of $5.0 million for acquired assets which were classified as purchased in-process research and development.

29

Stock-Based Compensation

We account for stock-based awards to employees and non-employees using the accounting provisions of Statement of Financial Accounting Standards (“SFAS”) No. 123R—accounting for Stock-Based Compensation,which provides for the use of the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. Shares of common and preferred stock issued in connection with acquisitions are also recorded at their estimated fair values. Fair values of equity securities issued are determined by management based upon independent valuations obtained by management.

In December 2004, the FASB revised its SFAS No. 123 (“SFAS No. 123R”). The revision establishes standards for the accounting of transactions in which an entity exchanges its equity instruments for goods or services, particularly transactions in which an entity obtains employee services in share-based payment transactions. The revised statement requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which the employee is required to provide service in exchange for the award.

We use the Black-Scholes options-pricing model to determine the fair value of each option grant as of the date of grant for expense incurred. In applying the Black-Scholes options-pricing model, we assumed no dividend yield, risk-free interest rates ranging from 1.62% to 4.65%, expected option terms ranging from 0.5 to 5 years, volatility factors ranging from 0% to 50%, share prices ranging from $0.02 to $8.00, and option exercise prices ranging from $1.05 to $8.00.

In all periods, stock-based compensation is classified in various categories in the financial statements including “interest expense” and general and administrative expense.

Income Taxes

We incurred net operating losses for the three and nine months ended June 30, 2006 and 2005, and consequently did not or will not be required to pay federal or foreign income taxes, but we did pay nominal state taxes in several states where we have operations. We have a federal net operating loss carryover of approximately $108.8 million as of June 30, 2006, which expires through 2025 and of which $30.0 million is subject to various Section 382 limitations.

30

Under Section 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a “loss corporation” as defined, there are annual limitations on the amount of the net operating loss and other deductions which are available to us. Due to the acquisition transactions in which we have engaged in recent years, we believe that the use of these net operating losses will be significantly limited.

In addition, the utilization of our net operating loss carryforwards may be further limited if we experience a change in ownership of more than 50% subsequent to last change in ownership of September 30, 2003. Accordingly, our net operating loss carryforward available to offset future federal taxable income arising before such ownership changes may be further limited.

Our ability to realize our deferred tax assets depends on our future taxable income as well as the limitations on usage discussed above. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized prior to its expiration. Because we believe the realization of our deferred tax assets is uncertain, we have recorded a valuation allowance to fully offset them.

Results of Operations

Three Months Ended June 30, 2006 Compared to the Three Months Ended June 30, 2005

Consolidated Results of Operations

Net Sales.Our net sales for the three months ended June 30, 2006 were $5.7 million, a decrease of $0.1 million, or 2%, from the three months ended June 30, 2005. The decrease in our consolidated net sales for the three months ended June 30, 2006 reflected a decrease of $0.3 million attributable to the cancellation of our co-promotion agreement with Primus, a reduction in sales of Histex I/E due to the manufacturer’s voluntary recall of this product and the decision to increase our reserves for chargebacks, rebates, and returns. This was offset by an increase of $0.6 million in net sales in our Biopharmaceutical Products and Services segment, primarily resulting from an increase of $0.6 million in our Biovest subsidiary’s sales.

Cost of Sales.Our cost of sales for the three months ended June 30, 2006 was $2.4 million, or 41% of net sales, compared to $1.9 million, or 35% of net sales, during the three months ended June 30, 2005. This represented a decrease of $0.4 million, or 22%, over the three months ended June 30, 2005. The increase in cost of sales as a percentage of net sales was attributable primarily to an increase in the sales of lower margin products in are specialty pharmaceutical segment and the decision to increase our reserves for chargebacks, rebates, and returns.

Research and Development Expenses.Our research and development costs were $3.5 million for the three months ended June 30, 2006, an increase of $0.3 million, or 11%, over the three months ended June 30, 2005. This increase included $0.5 million in SinuNase development. Biovest research and development expense increased from $2.5 million in the three months ended June 30, 2005 to $3.0 million in the three months ended June 30, 2006 due to increased emphasis on BiovaxID product development.

Sales and Marketing expenses.Our sales and marketing expenses were $4.2 million for the three months ended June 30, 2006; a decrease of $0.1 million, or 1%, below the three months ended June 30, 2005.

General and Administrative Expenses.Our general and administrative expenses were $5.1 million for the three months ended June 30, 2006, an increase of $0.3 million, or 6%, below the three months ended June 30, 2005.

Interest Expense, net.In the three months ended June 30, 2006, our net interest expense was $2.2 million, an increase of $1.5 million, over the three months ended June 30, 2005. The increase was due primarily to interest on our Laurus term note, Laurus revolver, and Hopkins II line of credit. Interest income in both years was nominal.

Preferred Stock Dividends. In the three months ended June 30, 2006, we incurred no dividend costs, compared to $0.1 million in the three months ended June 30, 2005. There was no dividend cost in the three months ended June 30, 2006 due to the conversion of all Series E preferred stock to common stock at our Initial Public Offering in November 2005. Dividends for the three months ended June 30, 2005 consisted of dividends accrued on our Series E preferred stock.

31

Segment Operating Results

	For the Three months ended June 30,
	2006				2005
	Amount		% of Segment Net Sales		Amount		% of Segment Net Sales
Net Sales:
Biopharmaceutical Products and Services-
Biovest	$	2,051,667			$	1,476,098
All other business units		2,562,280				2,526,586
Total Biopharmaceutical Products and Services		4,613,947				4,002,684
Specialty Pharmaceuticals		1,112,580				1,605,623
Total Net Sales	$	5,726,527			$	5,608,307
Cost of Sales:
Biopharmaceutical Products and Services-
Biovest	$	1,149,090			$	776,287
All other business units		598,091				683,831
Total Biopharmaceutical Products and Services		1,747,181	38	%		1,460,118	36	%
Specialty Pharmaceuticals		618,794	56	%		484,134	30	%
Total Cost of Sales	$	2,365,975			$	1,944,252
Gross Margin:
Biopharmaceutical Products and Services-
Biovest	$	902,577			$	699,811
All other business units		1,964,189				1,842,755
Total Biopharmaceutical Products and Services		2,866,766	62	%		2,542,566	64	%
Specialty Pharmaceuticals		493,786	44	%		1,121,489	70	%
Total Gross Margin	$	3,360,552			$	3,664,055
Research and Development Expenses:
Biopharmaceutical Products and Services
Biovest	$	3,047,970			$	2,513,144
All other business units		484,759				681,153
Total Biopharmaceutical Products and Services		3,532,729	77	%		3,194,297	80	%
Specialty Pharmaceuticals		—	0	%		—	0	%
Total Research and Development Expenses	$	3,532,729			$	3,194,297
Sales and Marketing Expenses:
Biopharmaceutical Products and Services
Biovest	$	28,469			$	29,927
All other business units		—				366,435
Total Biopharmaceutical Products and Services		28,469	1	%		396,362	10	%
Specialty Pharmaceuticals		4,191,812	377	%		3,873,362	241	%
Total Sales and Marketing Expenses	$	4,220,281			$	4,269,724

Biopharmaceutical Products and Services

Net Sales.Net sales in our Biopharmaceutical Products and Services segment for the three months ended June 30, 2006, including net sales to related parties, were $4.6 million, an increase of $0.6 million, or 15%, from the three months ended June 30, 2005. This increase was attributable primarily to an increase in sales of $0.6 million in our Biovest subsidiary and an increase of $0.2 million in our Analytica subsidiary.

32

Cost of Sales.Our cost of sales in the Biopharmaceutical Products and Services segment for the three months ended June 30, 2006 was $1.7 million, or 38% of segment net sales, compared to $1.5 million, or 37% of segment net sales, during the three months ended June 30, 2005.

Research and Development Expenses.Our research and development costs in the Biopharmaceutical Products and Services segment were $3.5 million for the three months ended June 30, 2006, an increase of $0.3 million, or 11%, over the three months ended June 30, 2005. This increase is due to increased emphasis on BiovaxID and the phase 3 clinical trial.

Sales and Marketing Expenses.Our sales and marketing expenses in the Biopharmaceutical Products and Services segment were $0.03 million in the three ended June 30, 2006; a decrease of $0.4 million, or 93%, over the three months ended June 30, 2005. This increase was attributable to our shift in emphasis in that segment away from cell culture products and services and more toward the development of BiovaxID.

Specialty Pharmaceuticals

Net Sales.Net sales in the Specialty Pharmaceuticals segment for the three months ended June 30, 2006, including net sales to related parties, were $1.1 million, a decrease of $0.5 million, or 44%, from the three months ended June 30, 2005 was primarily attributable to a decrease in co-promotion revenue of $.3 million attributable to the cancellation of the Primus agreement and a reduction in sales of Histex I/E due to the manufacturers voluntary recall of this product, and a decision to increase our reserves for chargebacks, rebates, and returns. This additional reserve is considered necessary due to the potential for returns attributable to the Histex I/E recall and the FDA’s guidance related to continued manufacturing of products containing carbinoxamine of which this segment promotes three products containing this ingredient under the Histex label.

Cost of Sales.Our cost of sales in the Specialty Pharmaceuticals segment for the three months ended June 30, 2006 was $0.6 million, or 56% of net sales, compared to $0.5 million, or 30% of net sales, during the three months ended June 30, 2005. The increase in cost of sales as a percentage of net sales was primarily due to a decision to increase our reserves for chargeback, rebates, and returns.

Research and Development Expenses.There were no research and development expenses in our Specialty Pharmaceuticals segment in either of the three month periods ended June 30, 2006 or 2005.

Sales and Marketing Expenses.Our sales and marketing expenses in the Specialty Pharmaceuticals segment were $4.2 million in the three months ended June 30, 2006; an increase of $0.3 million, or 8%, over the three months ended June 30, 2005. This increase was primarily due to expenses related to the launch of MD Turbo.

Nine Months Ended June 30, 2006 Compared to the Nine Months Ended June 30, 2005

Consolidated Results of Operations

Net Sales.Our net sales for the nine months ended June 30, 2006 were $19.6 million, an increase of $1.9 million, or 11%, from the nine months ended June 30, 2006. The increase in our consolidated net sales for the nine months ended June 30, 2005 reflected an increase of $2.0 million in net sales in our Biopharmaceutical Products and Services segment, primarily resulting from a $1.3 million increase in net sales of our Biovest subsidiary and a $1.1 million increase in net sales of our Analytica International subsidiary. The increase in our consolidated net sales for the nine months ended June 30, 2006 also reflected a $0.3 million decrease in net sales in our Specialty Pharmaceuticals segment.

Cost of Sales.Our cost of sales for the nine months ended June 30, 2006 was $6.9 million, or 35% of net sales, compared to $6.3 million, or 36% of net sales, during the nine months ended June 30, 2005. This represented an increase of $0.6 million, or 9%, over the nine months ended June 30, 2005.

Research and Development Expenses.Our research and development costs were $9.7 million for the nine months ended June 30, 2006, an increase of $2.1 million, or 27%, over the nine months ended June 30, 2005. This increase included $1.5 million in SinuNase development compared to $1.2 million in SinuNase development for the same period last year. Biovest research and development expense increased from $6.3 million in the nine months ended June 30, 2005 to $8.2 million in the nine months ended June 30, 2006 due to increased emphasis on BiovaxID and its phase 3 clinical trial.

33

Sales and Marketing expenses.Our sales and marketing expenses were $1.1 million for the nine months ended June 30, 2006; a decrease of $0.6 million, or 5%, over the nine months ended June 30, 2005. This decrease was due in part to $1.1 million of decreased costs in our Biopharmaceutical Products and Services segment resulting from our shift in emphasis in that segment away from cell culture products and services and more toward the development of BiovaxID. This decrease was offset by higher costs of $0.5 million in our Specialty Pharmaceutical segment due in part to expenses related to the launch of MD Turbo and Xodol 7.5/300 and 5.0/300.

General and Administrative Expenses.Our general and administrative expenses were $16.3 million for the nine months ended June 30, 2006, an increase of $1.7 million, or 12%, over the nine months ended June 30, 2005. This increase was a result of the growth of our corporate infrastructure necessary to support your business and costs associated with being a public company.

Interest Expense, net.In the nine months ended June 30, 2006, our net interest expense was $4.4 million, an increase of $2.2 million, over the nine months ended June 30, 2005. The increase was due primarily to interest on our Laurus term note, Laurus revolver, and Hopkins II line of credit. Interest income in both years was nominal.

Preferred Stock Dividends. In the nine months ended June 30, 2006, we incurred dividend costs of $0.04 million, compared to $5.3 million in the nine months ended June 30, 2005. There was minimal dividend cost in the nine months ended June 30, 2006 due to the conversion of all Series E preferred stock to common stock at our Initial Public Offering in November 2005. Dividends for the three months ended June 30, 2005 consisted of dividends accrued on our Series E preferred stock.

Segment Operating Results

	For the Nine months ended June 30,
	2006				2005
	Amount		% of Segment Net Sales		Amount		% of Segment Net Sales
Net Sales:
Biopharmaceutical Products and Services-
Biovest	$	5,425,638			$	4,086,566
All other business units		7,885,592				7,048,827
Total Biopharmaceutical Products and Services		13,311,230				11,135,393
Specialty Pharmaceuticals		6,287,188				6,565,225
Total Net Sales	$	19,598,418			$	17,700,618
Cost of Sales:
Biopharmaceutical Products and Services-
Biovest	$	2,980,532			$	2,996,185
All other business units		2,010,069				1,823,639
Total Biopharmaceutical Products and Services		4,990,601	37	%		4,819,824	43	%
Specialty Pharmaceuticals		1,901,762	30	%		1,511,917	23	%
Total Cost of Sales	$	6,892,363			$	6,331,741
Gross Margin:
Biopharmaceutical Products and Services-
Biovest	$	2,445,106			$	1,090,381
All other business units		5,875,523				5,225,188
Total Biopharmaceutical Products and Services		8,320,629	63	%		6,315,569	57	%
Specialty Pharmaceuticals		4,385,426	70	%		5,053,308	77	%
Total Gross Margin	$	12,706,055			$	11,368,877
Research and Development Expenses:
Biopharmaceutical Products and Services
Biovest	$	8,206,961			$	6,626,480
All other business units		1,449,874				951,726
Total Biopharmaceutical Products and Services		9,656,835	73	%		7,578,206	68	%
Specialty Pharmaceuticals		—	0	%		—	0	%
Total Research and Development Expenses	$	9,656,835			$	7,578,206
Sales and Marketing Expenses:
Biopharmaceutical Products and Services
Biovest	$	117,689			$	229,906
All other business units		320,946				1,287,213
Total Biopharmaceutical Products and Services		438,635	3	%		1,517,119	14	%
Specialty Pharmaceuticals		10,640,347	169	%		10,142,898	154	%
Total Sales and Marketing Expenses	$	11,078,982			$	11,660,017

34

Biopharmaceutical Products and Services

Net Sales.Net sales in our Biopharmaceutical Products and Services segment for the nine months ended June 30, 2006, including net sales to related parties, were $13.3 million, an increase of $2.2 million, or 20%, from the nine months ended June 30, 2005. This increase was attributable primarily to an increase in sales of $1.1 million in our Analytica subsidiary and an increase of $1.1 million in sales of instrument hardware and disposals.

Cost of Sales.Our cost of sales in the Biopharmaceutical Products and Services segment for the nine months ended June 30, 2006 was $4.9 million, or 37% of segment net sales, compared to $4.8 million, or 43% of segment net sales, during the nine months ended June 30, 2005.

Research and Development Expenses.Our research and development costs in the Biopharmaceutical Products and Services segment were $9.7 million for the nine months ended June 30, 2006; an increase of $2.1 million, or 27%, over the nine months ended June 30, 2005. This increase included additional expenses relating to our BiovaxID project, as well as $1.5 million in SinuNase development expenses.

Sales and Marketing Expenses.Our sales and marketing expenses in the Biopharmaceutical Products and Services segment were $0.4 million in the nine ended June 30, 2006; a decrease of $1.1 million, or 11%, over the nine months ended June 30, 2005. This decrease was attributable to our shift in emphasis in that segment away from cell culture products and services and more toward the development of BiovaxID.

Specialty Pharmaceuticals

Net Sales.Net sales in the Specialty Pharmaceuticals segment for the nine months ended June 30, 2006, including net sales to related parties, were $6.3 million, an decrease of $0.3 million, or 4%, from the nine months ended June 30, 2005. This decrease was primarily attributable to a decrease in Histex I/E sales due to the manufacturer’s voluntary recall of the product, and a decision to increase reserves for chargebacks, rebates, and returns. This additional reserve is considered necessary due to the potential for returns attributable to the Histex I/E recall and the FDA’s guidance related to continued manufacturing of products containing carbinoxamine of which this segment promotes three products containing this ingredient under the Histex label.

Cost of Sales.Our cost of sales in the Specialty Pharmaceuticals segment for the nine months ended June 30, 2006 was $1.9 million, or 30% of net sales, compared to $1.5 million, or 23% of net sales, during the nine months ended June 30, 2005. The increase in cost of sales as a percentage of net sales was attributable to a change of product sales mix due to the introduction of MD Turbo during the quarter ended June 30, 2006 which has a higher cost of goods and less sales of the Histex line with a lower cost of sales, and the decision to increase our reserves for chargebacks, rebates, and returns.

Research and Development Expenses.There were no research and development expenses in our Specialty Pharmaceuticals segment in either of the nine month periods ended June 30, 2006 or 2005.

Sales and Marketing Expenses.Our sales and marketing expenses in the Specialty Pharmaceuticals segment were $10.6 million in the nine months ended June 30, 2006; an increase of $0.5 million, or 5%, over the nine months ended June 30, 2005. This increase was primarily due to expenses related to the launch of MD Turbo in addition to the launch of Xodol 7.5/300 and 5.0/300.

35

Liquidity and Capital Resources

Sources of Liquidity

We are anticipating that operating cash flow deficits will be offset by net cash inflows from financing activities, such as debt or equity placements, and accessing existing or new credit facilities, and receipt of repayment of inter-company demand loans. At June 30, 2006, we had $ 5.3 million in cash, including $5.0 million in restricted cash, $4.1 million in accounts receivable, $1.1 million of earned but unbilled receivables, and $3.8 million in availability under existing lines of credit.

We are currently engaged in efforts to restructure certain of our existing indebtedness in order to increase available funds on a near-term basis. Additionally, both Accentia and its subsidiary, Biovest, also intend to seek additional financing through one or more public or private equity offerings, additional debt financings, corporate collaborations or licensing transactions. If Biovest is successful in consummating additional financings it is anticipated that Biovest may repay some or all of the outstanding inter-company demand notes payable to Accentia and thereafter Biovest will commence the funding of its ongoing operations without additional inter-company loans from Accentia.

We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available from the foregoing sources, or if we determine it to otherwise be in the Company’s best interest, we may consider additional strategic financing options, including sales of assets or business units (such as specialty pharmaceuticals, market services or cell culture equipment) that are non-essential to the ongoing development or future commercialization of SinuNase, or we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs or curtail some of our commercialization efforts. There are currently no commitments in place for any debt or equity financing being sought by us or by Biovest, excluding future NMTC transactions, nor can assurances be given that such financing will be available. While we are confident that we will raise the capital necessary to fund operations and achieve successful commercialization of the products under development, there can be no assurances in that regard.

Debt Financing

As of June 30, 2006, our long-term debt, including accrued but unpaid interest, current maturities of long-term debt, and lines of credit, not including discount was $31.7 million. We currently have credit facilities with various lenders, including the following:

Credit Facility with Laurus Master Fund, Ltd.,Accentia -Under a credit facility with Laurus Master Fund, Ltd., or Laurus, at June 30, 2006, we had total borrowing availability of up to $15.0 million. We entered into this credit facility in April 2005, and it has been amended in August 2005, December 2005, and February 2006. A total of $14.2 million in principal and $0.2 million in accrued but unpaid interest was outstanding under this credit facility as of June 30, 2006. The Laurus credit facility consists of two components: a term loan in the principal amount of $10.0 million, under which $9.7 million in principal and $0.1 million in accrued but unpaid interest were outstanding as of June 30, 2006, and a revolving loan of up to $5.0 million, under which $4.5 million in principal and $0.1 million in accrued but unpaid interest were outstanding as of June 30, 2006. Under the revolving loan portion of the credit facility, we have the right to borrow up to the sum of 85% of all of eligible accounts receivable and 50% of eligible inventory and other assets pledged to secure the loan (with the eligibility criteria being set forth in the loan agreements). The Laurus credit facility is secured by a first priority security interest in all of the tangible and intangible assets of Accentia Biopharmaceuticals, Inc. and our Analytica subsidiary (including the stock of their respective subsidiaries). This security interest does not extend to any assets of our TEAMM, Biovest, or foreign subsidiary. The notes are also secured by certain publicly traded securities owned by the Francis E. O’Donnell Jr. Irrevocable Trust #1. The principal and accrued but unpaid interest under the Laurus credit facility is convertible by Laurus into shares of our common stock at a fixed conversion price of $6.80 per share, provided that there are certain limitations on when and how much of the loan can be converted at any one period of time, and further provided that no more than $2.5 million of the revolving loan can be converted into shares of our common stock.

The term loan portion of the Laurus credit facility accrues interest at a rate of the greater of 10.00% per annum or prime rate plus 4%. The revolving loan portion of the credit facility accrues interest at a rate equal to the greater of 7.75% per year or prime rate plus 2%. The term loan under the Laurus credit facility is payable through April 29, 2008 in equal monthly payments of principal and interest of $0.3 million. The revolving loan is due on April 29, 2008, with all accrued but unpaid interest payable monthly. We have the right to redeem the Laurus notes at any time at a redemption price equal to 130% of the principal amount plus all accrued but unpaid interest, subject to the right of Laurus to convert the notes prior to a redemption, provided that any portion of the revolving loan that exceeds $2.5 million can be prepaid at any time without penalty. Under the terms specified in our agreements with Laurus and subject to certain volume limitations, Laurus will be required to convert certain amounts under credit facility into shares of our common stock if there is an effective current registration statement in place covering the resale of shares issuable to Laurus under the credit facility and if the market price of our common stock reaches $10.00 per share. Also in connection with the Laurus credit facility, as amended, we

36

issued to Laurus warrants to purchase up to 1 million shares of our common stock at an exercise price of $8.00 per share, 277,778 shares of our common stock at an exercise price of $.001 per share, and 113,000 shares of our common stock at an exercise price of $.01 per share.

Credit Facility with Laurus Master Fund, Ltd.,Biovest –On March 31, 2006, our majority-owned subsidiary, Biovest closed a financing transaction (the “Transaction”) with Laurus, pursuant to which Laurus purchased from Biovest a secured promissory note in the principal amount of $7,799,000 (the “Note”) and a warrant to purchase up to 18,087,889 shares of Biovest’s common stock at an exercise price of $.01 per share (the “Warrant”). Since June 2003 the Company has been the primary source of financing for Biovest; however, this Transaction with Laurus represents the initial financing by Biovest from sources other than Accentia.

The Note and Warrant were purchased pursuant to a Note and Warrant Purchase Agreement between Biovest and Laurus (the “Purchase Agreement”). The following describes certain material terms of the Biovest Transaction:

• Under the terms of the Note, $299,000 of the principal amount was disbursed at the closing of Laurus and other third parties to cover closing fees and expenses relating to the transaction, and $7,500,000 of the principal amount was deposited into a restricted bank account of Biovest (the “Restricted Account”) pursuant to a restricted account agreement between Biovest and Laurus.

• Under otherwise agreed by Laurus is expected to authorize disbursements from the Restricted Account as the Company is able to secure additional working capital financing, including without limitation through financings involving New Market Tax Credits in the amounts and of the type more particularly described in the Transaction documents. On April 28, 2006, $2.5 million was released from the restricted account as part of a financing transaction involving New Market Tax Credits.

• The Note will become due and payable on March 31, 2009, provided that any portion of the principal amount not contained in the Restricted Account will be amortized in equal monthly payments of principal and interest beginning on July 1, 2006 and ending on the maturity date. The initial monthly payment amount will be $9,060.61 per month, provided that as amounts are released from the Restricted Account from time to time, such amounts will be added to the amortizing portion of the Note, and the monthly payments will increase accordingly. The Note can be prepaid by Biovest at any time without penalty.

• The outstanding principal amount of the Note will bear interest at a rate equal to the greater of the prime rate plus 2% or 9% per annum, except that any portion of the principal amount contained in the Restricted Account will bear interest at prime rate.

• Sixty-four percent (64%) of the Note is guaranteed by Accentia. We also have a separate credit facility with Laurus pursuant to which Accentia has pledged its assets as collateral, and pursuant to the Transaction documents, this pledge of collateral by Accentia will also secure our guarantee of the Note. Additionally, all of the assets of Biovest, including its intellectual property and the stock of Biovax, Inc. subsidiary, were pledged by Biovest as collateral of the Note and Obligations to Laurus.

• The Warrant provides that Laurus may purchase up to 18,087,889 shares of Biovest’s common stock at an exercise price equal to $.01 per share. The Warrant will expire on March 31, 2021.

• In connection with the Transaction, Laurus and Biovest entered into a registration agreement providing that Laurus will have the right to require Biovest to file a registration statement with the U.S. Securities and Exchange Commission to register the resale of the shares issuable to Laurus pursuant to the exercise of the warrant. Biovest will be required to file such registration statement within sixty (60) days after written demand by Laurus, provided that in no event will Biovest be required to file such registration statement earlier than ninety (90) days after the closing of the Transaction.

The note payable provides for monthly payment provisions, a variable interest feature that includes a cap of 9.0% and a default put at 130% of face value for certain contingent events, including service defaults and changes in control, for the amortizing portion of the arrangement; these features are not present for unreleased, non-amortizing balances. The Company evaluated all terms and conditions of the amortizing notes for indications of embedded derivative financial instruments. While the interest rate cap was found to be clearly and closely related to the host instrument, the Company determined that the default put did not meet the clearly and closely related criteria as provided in FASB 133 Derivative Financial Instruments. Accordingly, upon release of funds underlying the first traunch, the Company reclassified an amount of $306,750 which represents the estimated fair value of the default put liability. The default put liability is initially and subsequently carried at fair value with changes recorded in income. As additional traunches are released in future periods, the Company will be required to recognize the default put liability associated with each release of funds.

37

Credit Facility with Missouri State Bank. In addition to the Laurus credit facility, in December 2005, we secured a $3.0 million subordinated revolving credit agreement with Missouri State Bank and Trust Company. In March of 2006 we were granted an incremental $1.0 million expansion of the existing credit facility, bringing to total credit facility to $4.0 million. This loan bears interest at prime per annum and has a January 2007 maturity date. The agreement is secured by the accounts receivable and inventory of our TEAMM subsidiary. Additionally, the agreement is secured by assets and personal guarantees of the Francis E. O’Donnell Jr. Irrevocable Trust #1, Steven Stogel and Dennis Ryll (directors and/or principal shareholders of our company). As of June 30, 2006, the entire $4.0 million credit facility had been drawn and was outstanding.

Credit Facility with Hopkins II. We are also a party to a bridge loan credit facility from The Hopkins Capital Group II, LLC, otherwise referred to as Hopkins II. Dr. Francis E. O’Donnell, our Chief Executive Officer and Chairman, is the sole manager of Hopkins II, and several irrevocable trusts established by Dr. O’Donnell collectively constitute the largest equity owners of Hopkins II. In August 2005, we entered into a bridge loan agreement with Hopkins II that provides for aggregate borrowing availability of up to $7.5 million in principal amount at an interest rate of 4.25% per annum simple interest. This loan (including all accrued interest) will become due upon the earlier of August 16, 2007 or the completion by our company of a debt or equity financing that results in proceeds of more than $35.0 million (net of underwriting discounts, commissions, or placement agent fees). We may prepay the bridge loan at any time without penalty or premium. Notwithstanding the foregoing, on the date on which the bridge loan becomes due or on which we desire to prepay the loan, we must not be in default under our credit facility with Laurus, and the remaining balance under the Laurus credit facility at such time must be $2.5 million or less. If both of these conditions are not satisfied, then the bridge loan will not become due and cannot be paid until the first day on which both of these conditions are satisfied. Under the bridge loan agreement with Hopkins II, we have the unconditional right to borrow up to $5.0 million in the aggregate upon ten days’ prior written notice to Hopkins II, provided that our right to borrow any amounts in excess of $5.0 million is conditioned upon us either being in default under our credit facility with Laurus or having less than $5.0 million cash on hand at the time of the advance. As of June 30, 2006, the net amount of $1.0 million in principal was outstanding under this facility and $0.04 million in accrued but unpaid interest was outstanding after principal of $3.2 million and accrued interest of $0.1 million was converted into common stock. No payments of principal or interest are due until the maturity date of the loan. The Hopkins II bridge loan is subordinate to the Laurus credit facility, provided that we may repay the bridge loan prior to the full satisfaction of our obligations to Laurus so long as the above-described conditions are satisfied.

Loan from McKesson Corporation.In October 2002, we entered into a credit facility with McKesson Corporation in the initial amount of approximately $10 million. As of September 30, 2005, prior to our initial public offering, approximately $6.0 million in principal and interest had been outstanding under this credit facility. During the nine months ended June 30, 2006, we reduced this indebtedness by $5.5 million, such that as of June 30, 2006, $0.8 million in principal remained outstanding under this loan. This loan bears interest at a rate of 10% per year and is secured all of the assets of Accentia Biopharmaceuticals, Inc., including its stock in each of its subsidiaries, as well as certain publicly traded securities owned by two irrevocable trusts established by Dr. O’Donnell.

Loan from Harbinger Mezzanine Partners, L.P. As of June 30, 2006, we had a loan outstanding from Harbinger Mezzanine Partners, L.P. in the principal amount $3.0 million plus $0.05 million in accrued interest. The outstanding balance as of June 30, 2006 takes into account a $5.0 million pay down of this loan during the nine months ended June 30, 2006. This loan bears interest at a rate of 13.5% per annum and will become due in June 2006, with interest payable monthly. The loan is secured by receivables, inventories, and intangible assets of our TEAMM subsidiary. The principal and accrued interest were paid July 13, 2006.

Other Financing Arrangements

In February 2004, we entered into a Biologics Distribution Agreement with McKesson Corporation that gives McKesson exclusive distribution rights for all of our biologic products (including Biovest biologic products) in the U.S., Mexico, and Canada. These distribution rights were granted to McKesson in exchange for a $3.0 million refundable deposit paid by McKesson to us. The agreement can be terminated by McKesson upon 180 days’ prior written notice, upon mutual written agreement, or upon our repurchase of McKesson’s distribution rights prior to FDA approval of our first biologic product. In order to repurchase the distribution rights, we must pay McKesson a cash payment equal to the greater of two times the amount of the $3.0 million refundable deposit, or $6.0 million, or 3% of the value of the shareholder’s equity at the time of termination. If the agreement is otherwise terminated, then we will be required to return the $3.0 million deposit to McKesson.

In September 2004, we sold an interest in our future royalties from SinuNase to PPD for a $2.5 million cash payment. Under this agreement, we are obligated to pay PPD cumulative minimum payments equal to at least $2.5 million by the end of calendar year 2009. In the event PPD terminates the agreement for breach, including for our failure to make the minimum payments, PPD has the right to require us to repurchase the royalty interest for a purchase price equal to $2.5 million, less all royalty payments made by us to PPD. For accounting purposes, this has been accounted for as a deposit on our balance sheet at September 30, 2005 and September 30, 2004, and will be amortized into revenues as corresponding royalties are earned by PPD, at which time our corresponding deposit

38

Financing Relationship with Biovest

In June 2003, we purchased 81% of the outstanding capital stock of Biovest International, Inc. for $20.0 million pursuant to an Investment Agreement with Biovest. Under the Investment Agreement, as amended, we paid $2.5 million in cash at closing, $2.5 million by a 90-day note, and the balance of $15.0 million by a non-interest-bearing promissory note. As of December 31, 2005, this note had been satisfied in full, and during the nine months ended June 30, 2006, we advanced an additional $7.1 million to Biovest in the form of an inter-company demand loan. This loan does not appear in our condensed consolidated financial statements because it is eliminated upon consolidation. Biovest is actively pursuing one of more financing transactions in the form of a debt financing, equity financing, or collaboration or licensing transaction. We anticipate that we will demand payment of the inter-company demand loan when Biovest completes an adequate financing transaction, although there is no assurance as to when and if Biovest will be able to complete such a financing.

Cash Flows for the Nine Months Ended June 30, 2006

For the nine months ended June 30, 2006, we used $19.7 million in cash to fund our operating activities. This consisted primarily of a net loss of $26.2 million and $2.9 million derivative gain, reduced by non-cash charges for $0.5 million of depreciation, $1.6 million in amortization of intangibles, $0.9 million of stock-based compensation, and $1.1 million in accretion of debt discounts. Cash increased primarily due to the $4.0 million change in accrued liabilities, $0.3 million change in accounts receivable, offset by $0.5 million payments for inventory, and $0.1 million for inventory deposits.

We used net cash in investing activities of $2.3 million for the nine months ended June 30, 2006, primarily consisting of payments for product rights of $1.6 million, and improvements to our Worcester laboratory facility and other furniture, equipment, and leasehold improvements of $0.7 million.

We had net cash flows from financing activities of $19.4 million for the nine months ended June 30, 2006, consisting primarily of $22.5 million in proceeds from the issuance common stock, and net funding from lines of credit of $3.4 million. We reduced debt by $10.1 million, received proceeds from a minority interest investment in Biovest of $1.7 million, received net proceeds from non-controlling investment in variable interest entity, and $2.5 million in restricted cash was released.

Our net working capital deficit at June 30, 2006 decreased from September 30, 2005 by $16.9 million to $23.7 million, which was attributed largely to the proceeds from our initial public offering and proceeds from the conversion of preferred stock to common stock. This was offset by a fiscal nine months 2006 loss that was funded through debt and equity proceeds and refinancing of certain short-term debt to long-term.

The amount of our net working capital, which had a deficit of $23.7 million at June 30, 2006, will continue to be affected by our accounts receivable, and we expect that our accounts receivable will grow in connection with an anticipated growth in revenues from sales of products in our Specialty Pharmaceuticals segment. At June 30, 2006, our net accounts receivable, and earned but unbilled receivables was $5.2 million, an increase of $0.1 million from September 30, 2005.

Cash Flows for the Nine Months Ended June 30, 2005

For the nine months ended June 30, 2005, we used $23.5 million in cash to fund our operating activities. This consisted primarily of a net loss of $28.6 million, an increase in accounts receivables of $0.4 million, increase in accounts payable of $2.0 million, increase in accrued expenses of $2.3 million, reduced by non-cash charges approximately $0.5 million in depreciation, $2.1 million in amortization of intangibles, $0.6 million in stock-based compensation, and $2.5 million loss on conversion of shareholder debt to preferred stock., derivative loss of $0.2 million, and other non-cash charges of $0.01 million.

We used net cash in investing activities of $4.6 million for the nine months ended June 30, 2005, primarily consisting of payments for product rights of $4.3 million, and furniture, fixtures and leasehold improvements of $0.4 million.

We had net cash flows from investing activities of $31.4 million, consisting primarily of the proceeds from the issuance of preferred stock of $19.1 million, proceeds from the issuance of common stock of $0.6 million, and proceeds from convertible debentures of $5.0 million. We reduced debt by $2.0 million, increased lines of credit by $1.8 million, and paid $0.3 million in dividends.

39

Our net working capital deficit at June 30, 2005 increased from September 30, 2004 by $11.3 million to $19.9 million, which was attributed largely to the derivative liability.

Contractual Obligations and Off-Balance Sheet Arrangements

The following chart summarizes our contractual payment obligations as of June 30, 2006. The long- and short-term debt, fixed milestone obligations and license fees are reflected as liabilities on our balance sheet as of June 30, 2006. Operating leases are accrued and paid on a monthly basis.

The amounts listed for license agreements represent our fixed obligations payable to distribution partners for licensed products. The amounts listed for minimum royalty payments do not include those royalties on net sales of our products that may be in excess or not subject to minimum royalty obligations.

The other contractual obligations reflected in the table include obligations to purchase product candidate materials contingent on the delivery of the materials and to fund various clinical trials contingent on the performance of services. These obligations also include long-term obligations, including milestone payments that may arise under agreements that we may terminate prior to the milestone payments being due. The table excludes contingent royalty payments that we may be obligated to pay in the future.

	Payments Due by Period
	Less than One Year		One to Two Years		Three to Five Years		After Five Years		Total
	(in thousands)
Long-term debt(a)	$	11,406	$	14,019	$	—	$	—	$	25,425
License agreements		300		—		—		—		300
Minimum royalty payments		1,500		2,950		1,563		—		6,013
Product manufacturing and supply agreements		240		308		—		—		548
Cooperative research and development agreement		180		255		—		—		435
Employment agreements		3,234		5,615		698		—		9,547
Operating lease obligations		2,061		2,966		1,660		—		6,687
	$	18,921	$	26,113	$	3,921	$	—	$	48,955

The above table does not include any additional amounts that we may be required to pay under license or distribution agreements upon the achievement of scientific, regulatory, and commercial milestones that may become payable depending on the progress of scientific development and regulatory approvals, including milestones such as the submission of drug approval applications to the FDA and approval of such applications. While we cannot predict when and if such events will occur, depending on the successful achievement of such scientific, regulatory and commercial milestones, we may owe up to $2.5 million, $8.8 million, and $5.0 million in twelve months ended June 30, 2006, 2007 and 2008, respectively.

Under the Biologics Distribution Agreement that we entered into with McKesson Corporation in February 2004, as described above, we granted McKesson exclusive distribution rights to our biologics products in exchange for a $3.0 million refundable deposit. McKesson has the right to terminate this agreement at any time upon 180 days’ prior written notice, and upon such termination, we will be required to refund the $3.0 million deposit to McKesson.

Under the September 2004 Royalty Stream Purchase Agreement with PPD, as described above, if PPD does not receive at least $2.5 million in royalties from SinuNase under this agreement by 2009, then PPD has the right to terminate the agreement. In the event of such a termination, we will be required to refund up to the $2.5 million which PPD paid to us upon the execution of the agreement in consideration of the future royalty rights, offset by any amounts paid to the date of termination. As of June 30, 2006, we had paid $0.1 million to PPD.

40

Under the promissory note that we issued to Biovest in connection with our June 2003 investment agreement with Biovest, a total of $15.0 million became payable to Biovest on various dates through June 2007. In August 2004, we entered into an amendment of the investment agreement under which we agreed to use reasonable efforts to make advances to Biovest under the note prior to the due date of the payments thereunder. We completed funding of our commitment under the note by December 31, 2005. At June 30, 2006, we had outstanding intercompany advances of $7.1 million.

We do not maintain any off-balance sheet financing arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

We are exposed to various market risks as a part of our operations, and we anticipate that this exposure will increase as a result of our planned growth. In an effort to mitigate losses associated with these risks, we may at times enter into derivative financial instruments, although we have not historically done so. These may take the form of forward sales contracts, option contracts, foreign currency exchange contracts, and interest rate swaps. We do not, and do not intend to, engage in the practice of trading derivative securities for profit.

Interest Rates

Some of our funds may be invested in short-term, interest-bearing, investment grade securities. The value of these securities will be subject to interest rate risk and could fall in value if interest rates rise. Due to the fact that we hold our excess funds in cash equivalents, a 1% change in interest rates would not have a significant effect on the value of our cash equivalents.

Foreign Exchange Rates

While we have operations in Germany, these operations are not significant to our overall financial results. Therefore, we do not believe fluctuations in exchange rates would have a material impact on our financial results.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. Our management, with the participation of our principal executive officer and principal financial officer, have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this quarterly report (the “Evaluation Date”). Based on such evaluation, our principal financial officer and principal executive officer have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective and designed to ensure that the information relating to our company (including our consolidated subsidiaries) required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the requisite time periods.

(b) Changes in Internal Controls. There was no change in our internal control over financial reporting (as defined in Rules 13a–15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, such controls.

Part II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Except for the following, we are not a party to any material legal proceedings, and management is not aware of any threatened legal proceedings, that could cause a material adverse impact on our business, assets, or results of operations:

In October 2002, our subsidiary, AccentRx, Inc, acquired the assets and certain liabilities of American Prescription Providers, Inc. and American Prescription Providers of New York, Inc., collectively referred to as APP, which at the time of purchase operated a mail-order specialty pharmacy focused on filling prescriptions for AIDS patients and organ transplants. Commencing in late 1998, Dr. Francis E. O’Donnell (our Chairman and Chief Executive Officer) was the Chairman of the Board of APP, Dr. Dennis L. Ryll (a director of our company) was a director of APP, and McKesson Corporation was APP’s principal lender. Also beginning in late 1998,

41

The Hopkins Capital Group, LLC, an entity in which Dr. O’Donnell is the manager, and MOAB Investments, LP, an entity in which Dr. Ryll is a limited partner, were principal stockholders of APP. Following the purchase of APP’s assets, AccentRx operated the mail-order business until it sold the assets of this business in December 2003 to a third-party in an arm’s length transaction. All of the sale proceeds from the disposition of this business were used to pay debts of AccentRx, including reducing the outstanding balance of the McKesson loan. After the sale of the APP assets, AccentRx ceased to engage in business, and AccentRx currently has nominal assets.

APP learned in May 2002 that the U.S. Department of Justice was conducting an industry-wide investigation under anti-kickback laws and other laws and regulations relating to purchases and sales of Serostim, an AIDS-wasting drug manufactured by Serono, Inc., from 1997 through 2000. As part of this investigation, in May 2002, APP received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts, and in March 2004, it received a federal grand jury subpoena seeking records related to Serostim prescriptions dispensed by APP, reimbursement claims submitted to Medicaid for Serostim, and APP’s relationships with Serono. We are not aware of any investigation into the acts of AccentRx or our company with regard to the conduct of the mail-order pharmacy business following AccentRx’s purchase of APP’s assets. While we are uncertain as to the amount or measure of damages, if any, that may be sought from APP, based on information currently available to us, we estimate that, from the commencement of business by APP on December 1, 1998 through 2000, Serono paid APP approximately $500,000 under a program for data collection, and during this same period, Medicaid reimbursed APP approximately $6,000,000 for Serostim prescriptions filled by APP. We estimate that the majority of these payments from Serono and reimbursements from Medicaid were not attributable to APP’s mail-order business, but rather were attributable to APP’s retail pharmacies, which APP sold to a third party in February 2001 and were therefore not acquired by AccentRx as a part of the 2002 acquisition of APP’s assets. In May 2005, the U.S. Attorney’s Office notified APP that it believes that APP has significant potential liability as a result of allegedly unlawful rebates and discounts paid to them by Serono between 1997 and 2000. In August 2005, the U.S. Attorney’s Office orally and informally indicated to our legal counsel that, as a result of these allegedly unlawful rebates and discounts, it was considering instituting a civil action against AccentRx, our company, APP (which has since dissolved and been liquidated), and shareholders of APP who received APP assets as a part of the liquidation of APP. However, it is not possible to predict the outcome of this investigation and whether the government will formally commence any action challenging any of APP’s prior programs and practices or APP’s liability or exposure as a result thereof. We are uncertain if any such action would be under the False Claims Act or other civil or criminal causes of action. In the event of litigation, we believe that APP will have defenses that will be vigorously asserted.

We cannot predict whether AccentRx or our company could be held liable for the prior acts of APP as a result of AccentRx’s purchase of APP’s assets or whether the government will commence any actions against AccentRx. However, we believe that it is unlikely that our company, which has always been operated as a distinct legal entity from AccentRx, will have material financial exposure in the event that AccentRx or APP incurs a material penalty in connection with this matter. Similarly, we do not believe that any adverse legal or regulatory determinations regarding APP, our company, or AccentRx or any persons associated with APP, our company, or AccentRx would have any material effect on the ability of our company and its subsidiaries to conduct their current or expected business operations. On October 17, 2005, the U.S. Department of Justice announced a settlement of criminal and civil allegations against Serono. According to the terms of the settlement, Serono, together with its U.S. subsidiaries and related entities, agreed to pay $704 million in connection with illegal schemes to promote, market, and sell its drug Serostim. We cannot predict the impact, if any, that this settlement will have on the government’s investigation relating to APP’s purchases and sales of Serostim.

ITEM 1A. RISK FACTORS

Not Applicable

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

On February 13, 2006, in connection with a modification of our credit facility with Laurus Master Fund, Ltd., we granted to Laurus an additional warrant to purchase up to 62,000 shares of our common stock at an exercise price of $0.01 per share. We claimed exemption from registration for this transaction under the Securities Act of 1933, as amended (the “Securities Act”), by virtue of Section 4(2) of the Securities Act and by virtue of Rule 506 of Regulation D. The grant of this warrant and the offer of the underlying shares did not involve any public offering, was made without general solicitation or advertising, and Laurus was an accredited investor with access to all relevant information necessary to evaluate the investment and represented to us that the warrant and underlying shares were being acquired for investment.

42

Use of Proceeds

We registered shares of our common stock in connection with our initial public offering under the Securities Act of 1933, as amended. (the “IPO”) Our Registration Statement on Form S-1 (Reg. No. 333-122769) in connection with our initial public offering was declared effective by the SEC on October 27, 2005. The offering closed on November 2, 2005. The underwriters of the offering were Jefferies & Company, Inc.; Ferris, Baker Watts incorporated; Stifel, Nicolaus & Company Incorporated; and GunnAllen Financial, Inc.

All 2.4 million shares of our common stock registered in the offering were sold at the initial public offering price (IPO) of $8.00 per share. The aggregate gross proceeds from the offering (before underwriting discounts and commissions) were $19.2 million. The net offering proceeds to us after deducting underwriting discounts and commissions of $1.3 million and total offering expenses of $3.6 million were $14.3 million. No payments for such expenses were made directly or indirectly to (i) any of our directors, officers or their associates, (ii) any person(s) owning 10% or more of any class of our equity securities or (iii) any of our affiliates.

Subsequent to our IPO and as of June 30, 2006, we had used all of the net proceeds of our IPO as follows:

(a) $1.3 million to fund milestone and similar product-related payments to our development partners in our specialty pharmaceuticals business for the acquisition on maintenance of product rights.

(b) $3.2 million to fund debt reductions as part of a plan to restructure existing debt in order to facilitate future financings. The restructuring plan included: (i) establishing a new credit facility with Missouri State Bank under which we borrowed $4.0 million; (ii) $2.0 million reduction in outstanding principal due under our credit agreement with Harbinger Mezzanine Partners and (iii) $5.2 million reduction in our outstanding debt to McKesson Corporation. While not a specified use of our IPO proceeds as described in our prospectus for the IPO, we elected to make the debt reductions because of the availability of a new credit facility with Missouri State Bank and because we believe the restructure plan will facilitate future debt and equity financing.

(c) $4.5 million to fund inter-company demand loans made to our subsidiary, Biovest, for its working capital, development and clinical trial activities. We anticipated that Biovest would have access to financing and accordingly we did not plan to use IPO proceeds to fund Biovest beyond the commitment in the Investment Agreement. While not a planned use of IPO proceeds as described in our prospectus for the IPO, we elected to fund these inter-company demand loans because of the continuing positive nature of the follow-up data from the Phase 2 clinical trial of BiovaxID, the continued progress in developing the AutovaxID automated production instrument. We anticipate that we will call these demand loans if Biovest completes an adequate debt or equity financing.

(d) $5.3 million to fund our additional working capital and general corporate purposes.

Options Exercised

In the nine months ended June 30, 2006, 29,828 common stock options were exercised.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5. OTHER INFORMATION

None

43

ITEM 6. EXHIBITS

The following exhibits are filed as part of, or incorporated by reference into, this quarterly report on Form 10-Q

Number	Description of Document
10.8	Amendment and Consent to Release between Biovest International, Inc. and Laurus Master Fund dated August 2, 2006
31.1	Certification of Chairman of the Board and Chief Executive Officer pursuant to Section 302 of Sarbanes – Oxley Act.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of Sarbanes – Oxley Act.
32.1	Certification of Chairman of the Board and Chief Executive Officer pursuant to Section 906 of Sarbanes – Oxley Act.
32.2	Certification of Chief Financial Officer pursuant to Section 906 of Sarbanes – Oxley Act

44

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ACCENTIA BIOPHARMACEUTICALS, INC.
	(Registrant)
Date: August 14, 2006	/s/ Francis E. O’Donnell, Jr., MD
	Francis E. O’Donnell, Jr., MD
	Chairman and Chief Executive Officer
	(Principal Executive Officer)
Date: August 14, 2006	/s/ Alan M. Pearce
	Alan M. Pearce
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

45